Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 22184. Отображено 100.
09-02-2012 дата публикации

Formulation for Prevention and Treatment of Bacterial Infections and Preparation Thereof

Номер: US20120034325A1
Автор: Ram Chander Vaidya, Shatrughna Prasad Vaidya
Принадлежит: Individual

The invention provides a formulation for the prevention and treatment of bacterial infections by administering an effective amount of the formulation comprising an extract of at least one plant selected from Allium sativum, Acorus calamus, Alstonia scholaris, Carissa spinarum, Cissampelos pareria, Chenopodium ambrosioides, Moringa olifera, Paederia foetida, Shorea robusta, Piper nigrum, Pueraria tuberosa, Ocimum sanctum, Terminalia bellirica, Tinospora cordifolia and Zingiber officinale , and a combination thereof. The invention also provides a process for preparing and method of using the same.

Подробнее
Номер записи: 1
05-04-2012 дата публикации

Compositions and Methods for Treatment and Management of Pain

Номер: US20120082739A1
Автор: Reza Ghorbani
Принадлежит: Individual

Disclosed herein are compositions and methods for the treatment and management of pain in a subject, comprising topically or orally administering a therapeutically effective amount of a composition comprising herbal extracts and compound mixtures to a subject. The composition includes turmeric extract, Boswellia extract, ginger extract, holy basil extract, rosemary extract, white willow extract and alpha lipolic acid

Подробнее
Номер записи: 2
27-09-2012 дата публикации

Herbal extracts and flavor systems for oral products and methods of making the same

Номер: US20120244084A1
Автор: Kenneth John Hughes, Roger Michael Browning, Sylvia Gaysinsky
Принадлежит: Individual

The invention provides a method for preparing an herbal extract and a flavor system comprising an herbal extract produced by the process. The invention also provides a flavor system comprising an herbal extract comprising thymol, eugenol, carvacrol and eucalyptol. The invention further provides a flavor system comprising a thyme extract having a minimum inhibitory concentration of less than about 3%. Additionally, the invention provides an oral product comprising a flavor system.

Подробнее
Номер записи: 3
29-11-2012 дата публикации

Method of assisting with digestive upsets using a confection-based delivery of peppermint oil and ginger

Номер: US20120301557A1
Автор: Dustin Garth James
Принадлежит: Enteral Health and Nutrition LLC

A confection for assisting with the relief of common digestive complaints is provided. The confection includes a carbohydrate base and an active agent infused into the carbohydrate base. The active agent includes at least one of ginger extract or peppermint oil.

Подробнее
Номер записи: 4
29-11-2012 дата публикации

Composition for improving blood circulation, containing extract of lindera obtusiloba as active ingredient

Номер: US20120301562A1
Автор: Jee Woong Lim, Jong-Hoon Kim, Jung-Duk Sohn, Jung-Ok Lee, Min-Ho Oak, Seung-Woo Lee, So-Hee Kang, Yongho Na, Youna Oh
Принадлежит: Han Wha Pharma Co Ltd, Yang Ji Chemical Co Ltd

Provided is a composition for improving blood circulation, comprising an extract of Lindera obtusiloba as an active ingredient, and more specifically, to a pharmaceutical composition and a health functional food for preventing and treating thrombotic disorders by improving blood circulation, comprising an extract of Lindera obtusiloba as an active ingredient. The extract of Lindera obtusiloba of the present invention and a crude purified product thereof can be obtained through extraction using various solvents such as water, ethanol, methanol, butanol, etc. Since the extract and the crude purified product have not only excellent inhibitory effect on platelet aggregation induced by various aggregation inductions in vitro, but also excellent inhibitory effect on rapid thrombus formation in vivo, they can be useful for preventing and treating diseases caused by blood circulation disorders such as thromboembolism, etc.

Подробнее
Номер записи: 5
03-01-2013 дата публикации

Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells

Номер: US20130004597A1
Автор: Chen-Yu LEE
Принадлежит: Individual

The present invention relates to herbal medicinal compositions and extracts thereof for inhibiting growth of cancer cells. One of the examples described in the present invention comprises Forsythiae fructus, Menthae Herba, Gardeniae Fructus, Scutellariae Radix, Lophatheri Folium, Glycyrrhizae Radix, Rhei Rhizoma, Na 2 SO 4 , and Atractylodis Rhizoma. The residual examples are described herein.

Подробнее
Номер записи: 6
10-01-2013 дата публикации

Ginger Extract for Inhibiting the Fat-storage Function of Adipocytes and a Medication thereof

Номер: US20130011500A1
Автор: Chia-Ju Chang, I-Min Liu, Shorong-Shii Liou
Принадлежит: Han Sheng Pharmtech Inc

In the present invention, a ginger extract for inhibiting the fat-storage function of adipocytes and a medication thereof is disclosed, wherein the ginger extract is obtained form Alpinia galangal and Zingiber zerumbet.

Подробнее
Номер записи: 7
10-01-2013 дата публикации

Stimulation of the synthesis of the activity of an isoform of lysyl oxidase-like loxl for stimulating the formation of elastic fibers

Номер: US20130011902A1
Автор: Charbel Bouez, Claudine Gleyzal, Corinne Reymermier, Eric Perrier, Odile Damour, Pascal Sommer, Valerie Andre, Valerie Cenizo
Принадлежит: BASF Beauty Care Solutions France SAS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

The invention relates to the stimulation of the synthesis and of the activity of an isoform of lysyl oxidase, and more particularly of the LOXL (lysyl oxidase-like) isoform. The invention relates notably to a method of identifying an active principle which stimulates the formation of elastic fibers. The aim of the invention is mainly to provide such a method of identification so as to provide compositions which enable stimulating the formation of elastic fibers.

Подробнее
Номер записи: 8
17-01-2013 дата публикации

Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells

Номер: US20130017275A1
Автор: Chen-Yu LEE
Принадлежит: Individual

The present invention relates to herbal medicinal compositions and extracts thereof for inhibiting growth of cancer cells. One of the examples described in the present invention comprises Forsythiae fructus, Menthae Herba, Gardeniae Fructus, Scutellariae Radix, Lophatheri Folium, Glycyrrhizae Radix, Rhei Rhizoma, Na 2 SO 4 , and Atractylodis Rhizoma. The residual examples are described herein.

Подробнее
Номер записи: 9
28-02-2013 дата публикации

Warming Inch Loss Delivery System

Номер: US20130052275A1
Автор: Michelle Ward
Принадлежит: Individual

This invention is a topical treatment for the skin, used for skin enhancement, firming, smoothing, refining and to reduce the appearance of cellulite; that has a self-warming or thermogenic effect comprised of a base combination of warming herbs (Ayurvedic), being any herbs that create a warming effect, combined with dietary minerals that can be blended together in any ratio.

Подробнее
Номер записи: 10
21-03-2013 дата публикации

DIETARY SUPPLEMENTS CONTAINING EXTRACTS OF CINNAMON AND METHODS OF USING SAME TO PROMOTE ENHANCED SIRTUIN, CELL AND TELOMERE INTEGRITY

Номер: US20130072574A1
Автор: Miller Peter J., Qin Bolin, Romero Augustin T., Romero Tim
Принадлежит: FHG Corporation d/b/a Integrity Nutraceuticals

A dietary supplement composition is provided for enhancing the expression of a sirtuin gene or protein. An inventive supplement composition includes at least one cinnamon extract containing at least 0.5% doubly linked Type-A polymers by dry weight. The cinnamon extract is derived from the or plant. In some embodiments, the cinnamon extract is present at approximately 20%-50% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is optionally provided in the composition. The dietary supplement composition is administered orally to promote expression or enhanced expression of a sirtuin gene or protein. 140-. (canceled)41. A process of increasing expression of a gene encoding a sirtuin in a subject comprising:administering to a subject a composition comprising at least 0.5 percent Type-A polymers by weight, andincreasing expression of a gene encoding a sirtuin in said subject by said step of administering.42. The process of claim 41 , wherein said composition further comprises one or more vitamins claim 41 , antioxidants claim 41 , sirtuin enhancers claim 41 , or combinations thereof.43. The process of wherein said Type-A polymers comprise single and doubly linked Type-A polymers.44. The process of wherein the composition is administered orally.45. The process of wherein said vitamin is vitamin A claim 42 , vitamin B claim 42 , vitamin C claim 42 , vitamin D claim 42 , vitamin E claim 42 , or vitamin K.46. The process of wherein said antioxidant is alpha lipoic acid claim 42 , acai claim 42 , astazanthin claim 42 , wolfberry claim 42 , glutathione claim 42 , or super oxide dismutase.47. The process of wherein the sirtuin enhancer is resveratrol or polygonum.48. The process of wherein said composition is administered daily for a period of twelve weeks or more.49. The process of further comprising quantifying the expression of a sirtuin gene in said subject subsequent to said administering.50. The process of further comprising quantifying the ...

Подробнее
Номер записи: 11
02-05-2013 дата публикации

Method for Preparing Raw Material for Functional Foods from Barley or Wheat Seeds

Номер: US20130108721A1
Автор: Lee Gyu-Gil
Принадлежит:

A method is provided for preparing a raw material for functional foods from vernalized, pre-germinated barley or wheat seeds, plumules cultured the vernalized, pre-germinated barley or wheat seeds, or a material resulting from the fermentation of the vernalized, pre-germinated barley or wheat seeds with lactic acid bacteria. 1. A method for increasing a functionality of barley or wheat seeds , comprising:(a) pre-germinating barley or wheat seeds; and(b) increasing the functionality of the pre-germinating barley or wheat seeds by vernalizing the pre-germinated barley or wheat seeds2. The method according to claim 1 , wherein the pre-germinating step is carried out by immersing barley or wheat seeds in water so that the seeds absorb a sufficient amount of water claim 1 , and incubating the barley or wheat seeds at 10˜25° C. for 10˜24 hrs to sprout 3˜5% of a total number of the seeds.3. The method according to claim 1 , wherein the vernalizing step is carried out by incubating the pre-germinated barley or wheat seeds at 0˜3° C. temperature and 80˜90% humidity for 40˜50 days.4. The method according to claim 1 , wherein the functionality is a functionality selected from the group consisting of antioxidant activity claim 1 , an anti-obesitic activity and an anti-diabetic activity.5. The method according to claim 1 , further comprising processing the pre-germinated claim 1 , vernalized barley or wheat seeds claim 1 , wherein the processing step is carried out by drying and pulverizing claim 1 , or squeezing the vernalized barley or wheat seeds claim 1 , or extracting the vernalized barley or wheat seeds with a solvent selected from among lower alcohols of 1 to 5 carbon atoms claim 1 , acetone claim 1 , ethyl acetate claim 1 , saturated normal butanol claim 1 , chloroform claim 1 , methylene chloride claim 1 , water claim 1 , and a mixture thereof.6. The method according to claim 1 , further comprising cultivating the pre-germinated claim 1 , vernalized barley or wheat ...

Подробнее
Номер записи: 12
09-05-2013 дата публикации

COMPOSITIONS FOR THE SYMPTOMATIC RELIEF OF STOMACH PAIN OR GASTROOESOPHAGEAL REFLUX

Номер: US20130115290A1
Автор: GAGO DE SANTOS ANGEL MANUEL
Принадлежит:

Compositions useful for relieving the symptoms commonly known as stomach acidity, heartburn or, more technically, esophageal reflux (GERD), that comprise a fatty acid and a plant extract. These compositions have been tried in patients with clinical records of previous diagnosis of GERD, chronic heartburn, or esophagitis, with a high degree of success. 2. The composition of claim 1 , wherein the plant extract from the alliaceae family is a garlic extract.3. The composition of claim 2 , wherein the garlic extract is powdered claim 2 , non-deodorized claim 2 , dry extract.4. The composition of claim 1 , wherein the alkali or alkaline-earth metal salt of at the least one C1-C10 fatty acid is a sodium claim 1 , calcium or potassium salt thereof.5. The composition of claim 4 , wherein the sodium claim 4 , calcium or potassium salt of the C1-C10 fatty acid is sodium butynate.6. The composition of claim 4 , wherein the sodium claim 4 , calcium or potassium salt of the C1-C10 fatty acid is buffered with a buffer selected front phosphate salts and carbonate salts.7. The composition of claim 1 , wherein the glycerol ester of at least one C1-C10 fatty acid is a triglyceride thereof.8. The composition of claim 1 , further comprising a curcuma plant extract.9. The composition of claim 1 , further comprising at least one excipient selected from the group consisting of vehiculizing agents claim 1 , thinners claim 1 , disintegrants claim 1 , lubricants claim 1 , binders claim 1 , gellants claim 1 , flavors claim 1 , sweeteners claim 1 , coloring agents claim 1 , preservatives claim 1 , fillers claim 1 , antioxidants claim 1 , encapsulating coadjuvants and coating agents.10. The composition of claim 1 , which is presented in the form of capsule claim 1 , pill claim 1 , sachet claim 1 , tablet or coated tablet.11. The composition of claim 1 , for the re-establishment of digestive homeostasis affected by peptic-acid disorders and/or states of disorder caused by damage to the gastric ...

Подробнее
Номер записи: 13
09-05-2013 дата публикации

METHOD FOR IDENTIFYING THERAPEUTIC AGENTS FOR TREATMENT OF CANCER

Номер: US20130116335A1
Автор: Langhans Sigrid Anne-Barbara, Lee Seung Joon
Принадлежит: The Nemours Foundation

The presence of phosphorylated Cdc27 in cancer cells is utilized to identify patients likely to benefit from treatment with a chemotherapeutic agent that binds to, or binds to and crosslinks, phosphorylated Cdc27, e.g., curcumin, or to determine whether patients undergoing such treatment will continue to respond effectively. Candidate compounds are screened for anticancer effect by testing the ability to bind to or crosslink phosphorylated Cdc27. 1. A method of identifying a patient with cancer who is most likely to benefit from treatment with an agent that binds phosphorylated Cdc27 , the method comprising:(a) obtaining a sample of cancer cells from the patient;(b) determining whether the sample comprises cancer cells that contain phosphorylated Cdc27; and(c) identifying the patient as one most likely to benefit from treatment with an agent that binds phosphorylated Cdc27, if the cancer cells comprise phosphorylated Cdc27.2. The method according to claim 1 , wherein the agent that binds phosphorylated Cdc27 crosslinks said phosphorylated Cdc27 claim 1 , and the method is for identifying the patient as one most likely to benefit from treatment with an agent that crosslinks phosphorylated Cdc27 claim 1 , if the cancer cells comprise phosphorylated Cdc27.3. A method of predicting whether a cancer patient is afflicted with a tumor that will respond effectively to treatment with an agent that binds phosphorylated Cdc27 claim 1 , the method comprising:(a) obtaining a sample of the patient's tumor;(b) determining whether the sample comprises tumor cells that contain phosphorylated Cdc27; and(c) predicting that the tumor will respond effectively to treatment with an agent that binds phosphorylated Cdc27, if tumor cells of the sample contain phosphorylated Cdc27.4. The method according to claim 3 , wherein the agent that binds phosphorylated Cdc27 crosslinks said phosphorylated Cdc27 claim 3 , and the method is for predicting that the tumor will respond effectively to ...

Подробнее
Номер записи: 14
16-05-2013 дата публикации

METHODS OF REDUCING 15-F2T-ISOP LEVELS IN MAMMALS

Номер: US20130123368A1
Автор: Kuhrts Eric
Принадлежит: BIOACTIVES, INC.

Methods of reducing 15-F-IsoP levels in mammalian subjects are disclosed herein. In addition, methods of reducing or preventing oxidative stress and treating or preventing related diseases are disclosed. 1. A method of reducing levels of 15-F-Isoprostane (15-F-IsoP) in a mammalian subject , said method comprising administering to said mammalian subject an amount of xanthohumol sufficient to reduce levels of 15-F-IsoP in said mammalian subject.2. The method of claim 1 , wherein levels of 15-F-IsoP are reduced in the urine of said mammalian subject.3. The method of claim 2 , wherein said amount of xanthohumol is sufficient to reduce levels of 15-F-IsoP by at least 10%.4. The method of claim 2 , wherein said amount of xanthohumol is sufficient to reduce levels of 15-F-IsoP by at least 20%.5. The method of claim 2 , wherein said amount of xanthohumol is sufficient to reduce levels of 15-F-IsoP by at least 30%.6. The method of claim 2 , wherein said amount of xanthohumol is sufficient to reduce levels of 15-F-IsoP by at least 40%.7. The method of claim 1 , wherein said xanthohumol is administered as a water-soluble formulation.8. The method of claim 7 , wherein said xanthohumol water-soluble formulation comprises: a) xanthohumol; and b) a non-ionic surfactant.9. The method of claim 8 , wherein said non-ionic surfactant is a non-ionic water soluble mono- claim 8 , di- claim 8 , or tri-glyceride; non-ionic water soluble mono- or di-fatty acid ester of polyethyelene glycol; non-ionic water soluble sorbitan fatty acid ester; polyglycolyzed glyceride; non-ionic water soluble triblock copolymers; or derivative thereof.10. The method of claim 8 , wherein said non-ionic surfactant is macrogolglycerol hydroxystearate.11. The method of claim 1 , wherein said amount of xanthohumol is at least 1 mg.12. The method of claim 1 , wherein said amount of xanthohumol is at least 3 mg.13. The method of claim 1 , wherein said amount of xanthohumol is at least 5 mg.14. The method of claim 1 , ...

Подробнее
Номер записи: 15
23-05-2013 дата публикации

Ginger Extract for Inhibiting the Fat-Storage Function of Adipocytes and a Medication Thereof

Номер: US20130129846A1
Автор: Chang Chia-Ju, LIOU Shorong-Shii, LIU I-Min
Принадлежит: Han Sheng Pharmtech, Inc.

In the present invention, a ginger extract for inhibiting the fat-store function of adipocytes and a medication thereof is disclosed, wherein the ginger extract is obtained form and In the present invention, said ginger extract is further administrated to a target in need for inhibiting fat-storage function of adipocytes in the target. 1. A method of inhibiting fat-storage function of adipocytes , said method comprising:administrating an effective amount of a ginger extract to a target in need thereof, wherein the ginger extract is obtained by a process comprising:{'i': Alpinia galanga', 'Zingiber zerumbet,', 'Alpinia galanga', 'Zingiber zerumbet', 'Alpinia galanga', 'Zingiber zerumbet', 'Alpinia galanga', 'Zingiber zerumbet;, 'providing roots or stems of and followed by drying the roots or stems of and till water contents of the roots or stems of and being lower than 10%, to obtain a dry and a dry'}{'i': Alpinia galanga', 'Zingiber zerumbet, 'preparing a ginger component by mixing the dry and the dry in a weight ratio of 1:3 to 3:1 and then extracting the ginger component with a solvent to obtain a liquid extract; and'}condensing the liquid extract.2. The method of inhibiting the fat-storage function of adipocytes as defined in claim 1 , wherein the solvent is selected from one of water claim 1 , methanol ethanol acetone claim 1 , ethane claim 1 , propane claim 1 , butane and hexane.3. The method of inhibiting the fat-storage function of adipocytes as defined in claim 1 , wherein the extracting comprises extracting the ginger component with the solvent in a weight ratio of 1:8 to 1:12.4. The method of inhibiting the fat-storage function of adipocytes as defined in claim 1 , wherein the extracting is processed via sonication.5. The method of inhibiting the fat-storage function of adipocytes as defined in claim 1 , wherein the drying is processed via lyophilization claim 1 , spray drying claim 1 , evaporation or heating drying.6. The method of inhibiting the fat- ...

Подробнее
Номер записи: 16
23-05-2013 дата публикации

METHODS AND COMPOSITIONS FOR IMPROVING THE HEALTH OF ANIMALS

Номер: US20130131183A1
Автор: DAROSZEWSKI Janusz, Dick Clayton Paul, Verzberger-Epshtein Isabella
Принадлежит: Chemaphor Inc.

The invention features compositions and methods for the administration of an oxidatively transformed carotenoid, or a fractionated component thereof, for improving the health of animals, such as increasing joint mobility, increasing activity, and improving coat quality. 1. A method of increasing joint mobility of an animal in need thereof or increasing the activity level in an animal , said method comprising administering to said animal a composition comprising oxidatively transformed carotenoid , or a fractionated component thereof , in an amount sufficient to increase said joint mobility or increase said activity level.2. (canceled)3. A method of improving or maintaining the coat quality of an animal , said method comprising administering to said animal a composition comprising oxidatively transformed carotenoid , or a fractionated component thereof , in an amount sufficient to improve or maintain said coat quality.4. (canceled)5. A method of reducing discoloration in an eye of an animal , said method comprising administering to said animal a composition comprising oxidatively transformed carotenoid , or a fractionated component thereof , in an amount sufficient to reduce said discoloration.6. The method of claim 1 , wherein said composition is administered daily.7. The method of claim 6 , wherein from 0.1 mg/kg body weight to 3 mg/kg body weight of oxidatively transformed carotenoid claim 6 , or a fractionated component thereof claim 6 , is administered to said animal daily.8. The method of claim 1 , wherein said composition is mixed with food and administered orally to said animal.9. The method of claim 8 , wherein said food is a wet animal food or a dry animal food or said food is in the form of a kibble claim 8 , a chew claim 8 , a tablet claim 8 , or a soft edible treat.10. (canceled)11. The method of claim 1 , wherein said composition is administered to said animal as an oral supplement.12. The method of claim 11 , wherein said oral supplement is a palatable ...

Подробнее
Номер записи: 17
06-06-2013 дата публикации

CURCUMIN COMPOSITIONS AND USES THEREOF

Номер: US20130143969A1
Автор: Chen Wei, Chiu Ming Heung, Liu Zhongfa
Принадлежит: The Ohio State University

A composition and method of increasing the bioavailability of curcumin is provided. A synergistic combination of excipient polymers provides increased bioavailability thereby increasing the plasma concentration of curcumin and its metabolite curcumin O-glucuronide. The curcumin pharmaceutical compositions are suitable for modifying DNA methylation and treating diseases such as cancer. 1. A pharmaceutical composition comprising:curcumin, andat least two excipient polymers selected from the group consisting of a polyethoxylated castor oil, a polyoxyethylene sorbitan ester, and a polyethylene glycol (PEG).2. The composition of claim 1 , wherein the at least two excipient polymers are a polyethylene glycol and at least one of a polyethoxylated castor oil and a polyoxyethylene sorbitan ester.3. The composition of claim 1 , wherein the polyethylene glycol has an average molecular weight selected from the group consisting of 200 claim 1 , 300 claim 1 , 400 claim 1 , 500 claim 1 , 600 claim 1 , and combinations thereof claim 1 , and wherein the polyoxyethylene sorbitan ester is selected from polysorbate 20 claim 1 , 30 claim 1 , 40 claim 1 , 50 claim 1 , 60 claim 1 , 65 claim 1 , 70 claim 1 , 80 claim 1 , 85 claim 1 , and combinations thereof.4. The composition of claim 1 , wherein the polyethoxylated castor oil is the reaction product of 35 moles of ethylene oxide with each mole of castor oil.5. The composition of claim 1 , wherein a volume ratio of a polyethylene glycol to a second excipient polymer ranges from about 1:99 to about 99:1.6. The composition of claim 5 , wherein the second excipient polymer is the polyethoxylated castor oil and the volume ratio is about 4:1 to about 1:1.7. The composition of claim 5 , wherein the second excipient polymer is the polyoxyethylene sorbitan ester and the volume ratio is about 10:1 to about 1:1.8. The composition of claim 1 , wherein the composition is a gel having a curcumin concentration within the range of about 40 mg/mL to ...

Подробнее
Номер записи: 18
13-06-2013 дата публикации

COMPOSITIONS OF HERBAL FORMULATIONS AND USES THEREOF

Номер: US20130149398A1
Автор: Alex Philip, Centola Michael, Payne Adam Joshua, YESUDAS Tomy
Принадлежит: HAUS BIOCEUTICALS, INC.

Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient. 1. A composition comprising a mixture of plant extracts , wherein the mixture comprises:a) at least one Group I plant extract and at least one Group II plant extract, wherein the at least one Group I plant extract and the at least one Group II plant extract are different;b) at least one Group I plant extract and at least one Group III plant extract, wherein the at least one Group I plant extract and the at least one Group III plant extract are different;c) at least one Group I plant extract and at least one Group IV plant extracts, wherein the at least one Group I plant extract and the at least one Group IV plant extract are different;d) at least one Group II plant extract and at least one Group III plant extracts, wherein the at least one Group II plant extract and the at least one Group III plant extract are different;e) at least one Group II plant extract and at least one Group IV plant extract, wherein the at least one Group II plant extract and the at least one Group IV plant extract are different;f) at least one Group III plant extract and at least one Group IV plant extract, wherein the at least one Group III plant extract and the at least one Group IV plant extract are different;g) at least one Group I plant extract, at least one Group II plant extract, and at least one Group III plant extract, wherein the at least one Group I plant extract, the at least one Group II plant extract, and the at least one Group III plant extract are different;h) at least one Group I plant extract, at least one Group II plant extract, and at least one Group IV plant extract, wherein the at least one Group I plant extract, the at least one Group II plant extract, and the at least one Group IV plant extract are different;i) at least one Group I plant extract, at ...

Подробнее
Номер записи: 19
04-07-2013 дата публикации

Composition for Reducing Side- and After-Effects of Cancer Treatment

Номер: US20130171279A1
Автор: Frankel David, Grearson John, Locke Jay
Принадлежит: PHYSICIANRX, LLC

A compound for consumption by cancer patients, or others currently suffering from side effects such as those commonly associated with chemotherapy, that supplies herbal tonics with certain properties believed to ameliorate many of the side effects discussed above, and which has taste masking properties that improve the patient's tolerance of the supplement and likelihood to consistently consume the supplement. The compound is a mixture generally containing three core components: whey protein, which has a number of significant health benefits for cancer patients; hepatoprotectant and/or nephroprotectant agents(s), which reduce damage to the kidneys and liver; and anti-emetic agent(s), which reduce nausea and vomiting. 1. A liquid composition comprising:whey protein;an anti-emetic; anda hepatoprotectant.2. The composition of wherein said anti-emetic provides the resultant taste profile of said composition.3. The composition of wherein said anti-emetic comprises ginger.4. The composition of wherein said hepaprotectant comprises milk thistle.5. The composition of further comprising a taste masking agent.6. The composition of wherein said taste masking agent comprises miraculin7. The composition of wherein the taste masking agent comprises a flavouring.8. A liquid composition consisting essentially of:whey protein;an anti-emetic; anda hepatoprotectant.9. The composition of wherein said anti-emetic provides the resultant taste profile of said composition.10. The composition of wherein said anti-emetic is selected from the group consisting of: ginger and peppermint.11. The composition of wherein said hepaprotectant is milk thistle.12. A method of treating the side effects of cancer treatment comprising administering a liquid composition comprising the following:whey protein;an anti-emetic; anda hepatoprotectant.13. The method of wherein said liquid composition is administered prior to a treatment being administered.14. The method of wherein said anti-emetic provides the ...

Подробнее
Номер записи: 20
04-07-2013 дата публикации

NOVEL USE OF RICE, RICE BRAN OR RICE HULL EXTRACT AS AN HISTAMINE RECEPTOR ANTAGONIST

Номер: US20130171280A1
Автор: Baek Nam-In, Cho Suengmok, Han Daeseok, Han Jin-Kyu, Jin Young-Ho, KIM Dong-Soo, Kim In-ho, Lee Chang-Ho, Sung Jae-Young
Принадлежит: KOREA FOOD RESEARCH INSTITUTE

Disclosed is a novel use of rice, rice bran or rice hull extract as a histamine receptor antagonist. The rice, rice bran or rice hull extract may be used as a natural antihistamine to prevent or treat allergic rhinitis, inflammatory bowel disease, asthma, bronchitis, nausea, gastric and duodenal ulcer, gastroesophageal reflux disease, sleep disorder, anxiety and depression. It provides comparable or better effect of decreasing sleep latency, increasing sleep duration and increasing non-REM sleep as compared to diazepam, which is currently used as sleeping drug. Derived from the natural product rice, rice bran or rice hull, it has no side effect such as cognitive impairment, resistance or dependency even after long-term use. 1. A pharmaceutical composition for inhibiting the activity of a histamine receptor , comprising rice , rice bran or rice hull extract as an active ingredient.2. The pharmaceutical composition for inhibiting the activity of a histamine receptor according to claim 1 , wherein the pharmaceutical composition for inhibiting the activity of a histamine receptor is for preventing or treating allergic rhinitis claim 1 , inflammatory bowel disease claim 1 , asthma claim 1 , bronchitis claim 1 , nausea claim 1 , gastric and duodenal ulcer claim 1 , gastroesophageal reflux disease claim 1 , sleep disorder claim 1 , anxiety and depression.3. The pharmaceutical composition for inhibiting the activity of a histamine receptor according to claim 2 , wherein the prevention or treatment of sleep disorder is to reduce sleep latency claim 2 , increase sleep duration or increase non-REM sleep.4. The pharmaceutical composition for inhibiting the activity of a histamine receptor according to claim 1 , wherein the rice claim 1 , rice bran or rice hull extract is an extract of rice claim 1 , rice bran or rice hull extracted using water claim 1 , an organic solvent or a mixture thereof.5. The pharmaceutical composition for inhibiting the activity of a histamine receptor ...

Подробнее
Номер записи: 21
29-08-2013 дата публикации

TOPICAL SANITIZER AND METHOD OF USE WITH GLOVES

Номер: US20130224273A1
Автор: Neuser Joseph H., Redmond Mark James
Принадлежит: THE IDEA FOLDER LLC

Topical sanitizer includes avenanthramides, which is an active component of oats that is beneficial to the skin. The topical sanitizer is used preferably in conjunction with gloves that have an inner coating that includes avenanthramides. By using topical sanitizer that includes avenanthramides before and after wearing gloves, the skin of the person wearing the glove is more exposed to the beneficial avenanthramides all during the workday, not just when wearing gloves. The result is healthier, much softer and more comfortable skin on the hands. 1. A method for conditioning skin on hands , the method comprising the steps of:providing a topical sanitizer that comprises avenanthramides;providing gloves that include a powder-free coating on a skin-contacting interior surface of the glove, the coating comprising avenanthramides; andproviding instructions for sanitizing hands using the topical sanitizer before donning the gloves and after removing the gloves.2. The method of wherein the topical sanitizer further comprises zinc acetate and wherein the coating further comprises zinc acetate.3. The method of wherein the topical sanitizer is selected from the group: alcohol-based sanitizing gel claim 1 , foam soap claim 1 , and alcohol-free sanitizing foam.4. The method of further comprising the steps of:a person using the topical sanitizer to sanitize the person's hands;the person donning the gloves on the person's hands;the person removing the gloves from the person's hands; andthe person using the topical sanitizer to sanitize the person's hands after removing the gloves.5. A hand conditioning system comprising:a topical sanitizer that comprises avenanthramides;gloves that include a coating on a skin-contacting interior surface of the glove, the coating comprising avenanthramides; andinstructions for sanitizing hands using the topical sanitizer before donning the gloves and after removing the gloves.6. The hand conditioning system of wherein the topical sanitizer further ...

Подробнее
Номер записи: 22
29-08-2013 дата публикации

PHARMACEUTICAL COMPOSITIONS OF CURCUMIN

Номер: US20130225689A1
Автор: Goda Chirag Chandrakant, Gogia Ashish Premkumar, Khamar Bakulesh Mafatlal, Khan Imran Ahmad, Laddha Ritu Nitin, Modi Indravadan Ambalal, Patravale Vandana Bharat, Shenoy Dinesh Balkunje, Shrivastava Rajneesh Ramesh
Принадлежит: CADILA PHARMACEUTICALS LIMITED

The present invention relates to stable liquid pharmaceutical compositions of curcumin or its pharmaceutically acceptable salts or its derivatives with higher curcumin concentration and improved bioavailability without the use of buffer and/or molecular aggregation inhibitor(s). In accordance with present invention the curcumin is in the solubilized form to make a stable liquid pharmaceutical composition. 1. A stable pharmaceutical composition comprising:curcumin, oil, solvent, and surfactant wherein the ratio of oil to solvent is about 0.83 to about 10, surfactant to solvent is about 1 to about 60, and surfactant to curcumin is about 3 to 15, with curcumin in the range of about 2 to about 20% w/w with respect to the pharmaceutical composition.2. The pharmaceutical composition as claimed in wherein oil is selected from: fractionated coconut oil claim 1 , caprylic/capric triglyceride or an oil containing fatty acid triglycerides claim 1 , preferably medium chain fatty acid triglycerides isopropyl myristate claim 1 , isopropyl palmitate claim 1 , ethyl linoleate or an oil containing ethyl oleate esters of fatty acids and monovalent alkanols propylene glycol dicaprylate claim 1 , propylene glycol dilaurate or an oil containing propylene glycol di-fatty acid esters claim 1 , and combinations thereof.3. The pharmaceutical composition as claimed in wherein surfactant is selected from polysorbate claim 1 , vitamin E TPGS and cremophor.4. The pharmaceutical composition as claimed in wherein the surfactant is preferably cremophor.5. The pharmaceutical composition as claimed in wherein solvent is selected from glycofurol claim 1 , polyethylene glycol claim 1 , glycerol claim 1 , polypropylene glycol claim 1 , propylene glycol claim 1 , glycerin claim 1 , N-methyl-2-pyrolidone and ethyl alcohol or mixture thereof.6. The solvent pharmaceutical composition as claimed in wherein the solvent is preferably mixture of propylene glycol and ethyl alcohol.7. The pharmaceutical ...

Подробнее
Номер записи: 23
05-09-2013 дата публикации

TOPICAL SANITIZER AND METHOD OF USE WITH GLOVES

Номер: US20130230610A1
Автор: Neuser Joseph H., Redmond Mark James
Принадлежит: THE IDEA FOLDER LLC

Topical sanitizer includes avenanthramides, which is an active component of oats that is beneficial to the skin. The topical sanitizer is used preferably in conjunction with gloves that have an inner coating that includes avenanthramides. By using topical sanitizer that includes avenanthramides before and after wearing gloves, the skin of the person wearing the glove is more exposed to the beneficial avenanthramides all during the workday, not just when wearing gloves. The result is healthier, much softer and more comfortable skin on the hands. 1. A foam soap comprising:cocamidopropyl betaine;PEG-80 sorbitan laurate;sodium trideceth sulfate;PEG-150 distearate; andavenanthramides.2. The foam soap of comprising:cocamidopropyl betaine that is 1.0 to 10% by weight of the foam soap;PEG-80 sorbitan laurate that is 5.0 to 40% by weight of the foam soap;sodium trideceth sulfate that is 5.0 to 40% by weight of the foam soap;PEG-150 distearate that is at least 1.0% by weight of the foam soap; andavenanthramides that are at least 0.4 parts per million by weight of the foam soap.3. The foam soap of comprising:cocamidopropyl betaine that is 2.0 to 15% by weight of the foam soap;PEG-80 sorbitan laurate that is 10 to 30% by weight of the foam soap;sodium trideceth sulfate that is 10 to 30% by weight of the foam soap;PEG-150 distearate that is 1.0 to 10% by weight of the foam soap; andavenanthramides that are 0.4 to 10 parts per million by weight of the foam soap.4. The foam soap of further comprising lactic acid and vitamin E.5. The foam soap of further comprising:cocamidopropyl betaine that is approximately 3.33% by weight of the foam soap;PEG-80 sorbitan laurate that is approximately 15% by weight of the foam soap;sodium trideceth sulfate that is approximately 15% by weight of the foam soap;PEG-150 distearate that is approximately 1.6% by weight of the foam soap;avenanthramides that are approximately 1.0 parts per million by weight of the foam soap;lactic acid in a quantity ...

Подробнее
Номер записи: 24
12-09-2013 дата публикации

CELLULOSE DERIVATIVES FOR ENHANCING BIOAVAILABILITY OF FLAVONOIDS

Номер: US20130237609A1
Автор: Edgar Kevin J., Ilevbare Grace, Li Bin, Taylor Lynne, Williams Stephanie M.
Принадлежит:

The present invention relates to delivery systems to enhance the bioavailability of flavonoids to improve human health. Flavonoids of interest include but are not limited to curcumin, resveratrol, ellagic acid, naringenin, and quercetin. Flavonoids are important in part because they are known to have beneficial effects on human health, including cardioprotective, antioxidant, and anticancer effects. Utility has been limited by low bioavailability, both in the sense of requiring high doses and in that it has been difficult to carry out proper dose-response studies in the absence of methods to control the actual dose administered. In addition to pharmaceutical applications, there are potential nutraceutical uses, for example in supplements that might be sold in health food stores and pharmacies. 1. A composition comprising a molecular dispersion of an amorphous solid compound in an amorphous polymer matrix which has increased solubility , stability , or bioavailability over a non-amorphous form of the compound.2. The composition of claim 1 , wherein the non-amorphous form of the compound is a Class II or Class IV drug according to the Biopharmaceutics Classification System in that it exhibits respectively high intestinal permeability but low solubility or low intestinal permeability and low solubility.3. The composition of claim 1 , wherein the amorphous solid is chosen from at least one of curcumin claim 1 , resveratrol claim 1 , ellagic acid claim 1 , naringenin claim 1 , and quercetin.4. The composition of claim 1 , wherein the amorphous polymer matrix is chosen from at least one of CA adipate claim 1 , CAB adipate claim 1 , CAP suberate claim 1 , CAP sebacate claim 1 , CAB suberate claim 1 , CAB sebacate claim 1 , CA suberate claim 1 , CA sebacate claim 1 , HPMCAS (hydroxypropylmethyl cellulose acetate succinate) claim 1 , CAPH (cellulose acetate phthalate) claim 1 , HPMCPH (hydroxypropylmethylcellulose phthalate) claim 1 , CAAdP (cellulose adipate ester) claim 1 ...

Подробнее
Номер записи: 25
19-09-2013 дата публикации

Magnetic Nanoparticle Formulations, Methods for Making Such Formulations, and Methods for their Use

Номер: US20130245357A1
Автор: Chauhan Subhash, Jaggi Meena, Yallapu Murali Mohan
Принадлежит: SANFORD RESEARCH/USD, a nonprofit Corporation Organized Under South Dakota Law

The present invention provides derivatized magnetic nanoparticles, methods for making such nanoparticles, and methods for their use. 1. A magnetic nanoparticle (MNP) comprising(a) a core MNP;(b) first layer of cyclodextrin over the core MNP; and(c) a second layer of a pluronic polymer over the cyclodextrin layer.2. The MNP of claim 1 , wherein the core MNP comprises iron claim 1 , nickel claim 1 , cobalt claim 1 , or derivatives thereof.3. The MNP of claim 1 , wherein the core MNP comprises iron oxide.4. The MNP of claim 1 , wherein the core MNP is between about 5 nm and about 30 nm in diameter.5. An MNP cluster claim 1 , comprising a plurality of MNPs according to claim 1 , wherein the MNP cluster is between about 50 nm and about 200 nm in diameter.6. The MNP cluster of claim 5 , wherein the MNP cluster is between about 75 nm and about 150 nm in diameter.7. The MNP of claim 1 , wherein the cyclodextrin is selected from the group consisting of α-cyclodextrin claim 1 , β-cyclodextrin claim 1 , and γ-cyclodextrin claim 1 , and derivatives thereof.8. The MNP of claim 1 , wherein the cyclodextrin comprises β-cyclodextrin claim 1 , or derivatives thereof.9. The MNP of claim 1 , wherein the MNP comprises a molar ratio of between about 1:40 to 1:300 cyclodextrin:metal ion in the core MNP.10. The MNP of claim 1 , wherein the pluronic polymer comprises an ethylene oxide/propylene oxide block copolymer.11. The MNP of claim 1 , wherein the MNP comprises a molar ratio of between about 1:1 and 1:10 cyclodextrin:pluronic polymer.12. The MNP of claim 1 , wherein the MNP further comprises a therapeutic loaded into or onto the MNP claim 1 , a cell-targeting compound bound to the MNP claim 1 , and/or a photosensitizer loaded into or onto the MNP.1315-. (canceled)16. A method for making magnetic nanoparticles (MNPs) claim 1 , comprising(a) precipitating metal salts in the presence of ammonia to obtain metal oxide core nanoparticles; and (i) cyclodextrin; and', '(ii) a pluronic polymer ...

Подробнее
Номер записи: 26
26-09-2013 дата публикации

Cosmetic or Dermatological Preparations Containing Licochalcone A or an Extract of Radix Glycyrrhizae inflatae, Containing Licochalcone A

Номер: US20130253068A1
Автор: Kolbe Ludger, Mundt Claudia, TOM DIECK Karen, WENSORRA Ursula, WOLBER Rainer
Принадлежит: Beiersdorf AG

Disclosed are cosmetic or dermatological preparations for the treatment or alleviation of erythema which comprise an aqueous extract of Radix or licochalcone A and optionally one or more ethoxylated or propoxylated raw materials and/or one or more polyols. 1. A cosmetic or dermatological composition , wherein the composition comprises licochalcone A and is associated with instructions to use the composition for at least one of the treatment and alleviation of erythema.2. The composition of claim 1 , wherein the composition comprises a plant extract which comprises licochalcone A.3Glycyrrhicae inflatae. The composition of claim 2 , wherein the composition comprises an extract of Radix which comprises licochalcone A.4. The composition of claim 1 , wherein the composition comprises from 0.0001% to 5% by weight of licochalcone A.5. The composition of claim 1 , wherein the composition comprises from 0.001% to 1% by weight of licochalcone A.6. The composition of claim 1 , wherein the composition further comprises at least one of an ethoxylated and a propoxylated raw material.7. The composition of claim 6 , wherein the composition further comprises at least one polyol.8. The composition of claim 1 , wherein the composition further comprises at least one polyol.9. The composition of claim 8 , wherein the composition comprises from 0.01% to 2% by weight of the at least one polyol.10. The composition of claim 8 , wherein the at least one polyol comprises butylene glycol.11. The composition of claim 7 , wherein the at least one polyol comprises butylene glycol.12. The composition of claim 6 , wherein the at least one of an ethoxylated and a propoxylated raw material comprises PPG-6-decyltetradeceth-30.13. The composition of claim 7 , wherein the at least one of an ethoxylated and a propoxylated raw material comprises PPG-6-decyltetradeceth-30 and the at least one polyol comprises butylene glycol.14Glycyrrhicae inflatae. The composition of claim 1 , wherein the composition ...

Подробнее
Номер записи: 27
10-10-2013 дата публикации

COMPOSITIONS AND METHODS FOR TREATMENT AND MANAGEMENT OF PAIN

Номер: US20130266673A1
Автор: Ghorbani Reza
Принадлежит:

Disclosed herein are compositions and methods for the treatment and management of pain in a subject comprising or consisting of topically or orally administering a therapeutic effective amount of a composition. The composition is made up of minute amounts of herbal extracts and compound mixtures to a subject. The composition includes turmeric extract, extract, ginger extract, holy basil extract, rosemary extract, white willow extract and alpha lipolic acid each in minute amounts. 1Boswellia. An herbal composition for the management of pain comprising turmeric extract , extract , ginger extract , holy basil extract , rosemary extract , willow bark extract and alpha lipolic acid and wherein each of said extracts and said alpha lipolic acid include an amount of active ingredients of between 0.00015% by wgt. and 0.01% by wgt.2Boswellia. The herbal composition for the management of pain according to claim 1 , which includes turmeric extract in an amount of between 0.00864% by wgt. and 0.01966% by wgt. claim 1 , extract in an amount of between 0.0063% by wgt. and 0.0077% by wgt. claim 1 , ginger extract in an amount of between 0.00045% by wgt. and 0.00055% by wgt. claim 1 , holy basil extract in an amount of between 0.00018% by wgt. and 0.00022% by wgt. claim 1 , rosemary extract in an amount of between 0.00054% by wgt. and 0.00066% by wgt. claim 1 , willow bark extract in an amount between 0.00135% by wgt. and 0.00165% by wgt. and alpha lipolic acid in an amount between 0.009% by wgt. and 0.011% by wgt.3Boswellia. The herbal composition for the management of pain according to claim 2 , which includes turmeric extract in an amount of about 0.0096% by wgt. claim 2 , extract in an amount of about 0.007% by wgt. claim 2 , ginger extract in an amount of about 0.0005% by wgt. claim 2 , holy basil extract in an amount of about 0.0002% by wgt. claim 2 , rosemary extract in an amount of about 0.0006% by wgt. claim 2 , willow bark extract in an amount of about 0.0015% by wgt. and ...

Подробнее
Номер записи: 28
17-10-2013 дата публикации

Epidermal Growth Factor Composition, A Process Therefor and Its Application

Номер: US20130272999A1
Автор: Ella Krishna Murthy, Vellimedu Srinivas Kannappa
Принадлежит:

A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant. 1. A composition comprising recombinant human epidermal growth factor present in a range of about 0.001% to about 0.9% (w/w); L-lysine hydrochloric acid present in the range of about 0.2% to about 0.5% (w/w) and mannitol present in the range of about 1% to about 10% (w/w) as stabilizers; sodium methyl paraben present in the range of about 0.016% to about 0.18% (w/w) and sodium propyl paraben present in the range of about 0.01% to about 0.02% (w/w) as preservatives; poly acrylic acid present in the range of about 0.25% to about 1% (w/w) as a thickening agent; water present in the range of about 50% to about 99.5% (w/v) as a carrier; triethanol amine present in an effective amount to maintain the pH of the composition between 6.3 to 6.4 as a pH regulating agent; glycerol present in the range of about 1% to about 2.5% (w/w) as a humectant; and a therapeutic agent present in a range of about 0.005% to about 0.5% (w/w).2. The composition of claim 1 , wherein the recombinant human epidermal growth factor is in a topical formulation in the form of gel claim 1 , spray claim 1 , ointment claim 1 , cream and lotion claim 1 , in oral formulation in the form of tablet and capsule claim 1 , or in parenteral formulation in the form of injections.3. The composition of claim 1 , wherein the therapeutic agent is an antiinfective agent silver sulphadiazine present in a range of about 0.005% to about 0.5% (w/w).4. The composition of claim 1 , wherein the therapeutic agent is a recombinant antibiotic lysostaphin present in the range of about 0.01% to about 0.1% (w/w).5. The composition of claim 1 , wherein the therapeutic agent ...

Подробнее
Номер записи: 29
17-10-2013 дата публикации

Water Soluble Composition Comprising Curcumin Having Enhanced Bioavailability and Process Thereof

Номер: US20130274343A1
Автор: Deshpande Jayant Venkatesh, Kulkarni Shrinivas Krishnarao
Принадлежит: OmniActive Health Technologies Ltd

The invention disclosed relates to a water-soluble composition having enhanced bioavailability useful for the treatment of depression which comprises a synergistic combination of curcumin, at least an antioxidant, a hydrophilic carrier and a fat. The invention also discloses a process for the preparation of the curcumin composition which comprises the steps of dissolving curcumin, at least one antioxidant, a hydrophilic carrier and a fat in a solvent to form a homogenous mass; warming the resultant mass at a temperature ranging from 25° C. to 60° C. for a period of 4 to 8 hours to obtain a dry wet mass; removing the solvent by evaporation to form dry mass and pulverizing the dry mass to form a fine powder. 1. A novel water-soluble composition having enhanced bioavailability useful for the treatment of depression which comprises of curcumin along with at least one antioxidant , a hydrophilic carrier and fat.2. A novel water-soluble composition of curcumin as claimed in claim 1 , wherein the amount of curcumin used in the composition ranges from 1 wt % to about 90 wt % of the total composition.32. A novel water-soluble composition of curcumin as claimed in & claims 1 , wherein the concentration of the antioxidant used ranges from 0.1% to 10% by weight of the total composition.4. A novel water-soluble composition of curcumin as claimed in to claims 1 , wherein the concentration of the antioxidant used ranges from 0.1% to 10% by weight of the total composition.5. A novel water-soluble composition of curcumin as claimed in to claims 1 , wherein the concentration of the hydrophilic carrier used ranges from 1% to 85% by weight of the total composition.6. A novel water-soluble composition of curcumin as claimed in to claims 1 , wherein the concentration of the fat used ranges from 0.1% to 25% by weight of the total composition.7. A novel water-soluble composition of curcumin as claimed in to claims 1 , wherein the antioxidant used is selected from the group consisting of ...

Подробнее
Номер записи: 30
24-10-2013 дата публикации

METHOD OF TREATING AIRWAY REMOLDING SYMPTOM

Номер: US20130281543A1
Автор: KO Ying-Chin, KUO Po-Lin
Принадлежит:

A method of treating airway remolding symptom caused by phthalate esters, by providing a medication comprising: a ginger compound selected from one of (a) [6]-shogaol, (b) [6]-shogaol and [10]-gingerol, (c) [6]-shogaol and [8]-gingerol, and (d) [6]-shogaol and [6]-gingerol, and an acceptable carrier or excipient, which can relieve, the airway remodeling symptoms of asthma, particularly to phthalate ester-induced airway remodeling, by suppressing the proliferation and migration of bronchial smooth muscle cells and reducing the instances of fatal asthma. 1. A method of treating airway remolding symptom caused by phthalate esters , by providing a medication comprising:a ginger compound selected from one of (a) [6]-shogaol, (b) [6]-shogaol and [10]-gingerol, (c) [6]-shogaol and [8]-gingerol, and (d) [6]-shogaol and [6]-gingerol, andan acceptable carrier or excipient.2. The method of treating airway remolding symptom caused by phthalate esters as defined in claim 1 , wherein medication suppresses the proliferation and migration of bronchial smooth muscle cells.3. The method of treating airway remolding symptom caused by phthalate esters as defined in claim 1 , wherein the phthalate esters includes buthylbenzyl phthalate claim 1 , bis-(2-ethylhexyl) phthalate claim 1 , dibutyl phthalate claim 1 , and diethyl phthalate. This is a continuous application of U.S. patent application Ser. No. 13/245,511 filed on Sep. 26, 2011.1. Field of the InventionThe present invention relates to a method of treating airway remolding symptom, particularly to a method of treating airway remolding symptom caused by phthalate esters.2. Description of the Related ArtAsthma is a common chronic inflammatory airway disease and is characterized by serious trachea inflammation, trachea hyperreactivity, and airway remodeling. It is reported that the airway remodeling symptom of asthma usually comes accompany with severe inflammation which is induced by allergies-sensitized epithelial cells, with the ...

Подробнее
Номер записи: 31
31-10-2013 дата публикации

COMPOSITION FOR PREVENTING OR TREATING LIVER TOXICITY COMPRISING GALGEUNTANG OR LACTIC ACID BACTERIA FERMENTED GALGEUNTANG

Номер: US20130287761A1
Автор: LEE Jae Hoon, LEE Ji Hye, MA Jin Yeul, UM Young Ran
Принадлежит:

The present invention relates to lactic acid fermented Galgeuntang, and a composition comprising the said lactic acid bacteria fermented Galgeuntang or Galgeuntang as an active ingredient, more particularly, to lactic acid fermented Galgeuntang prepared by the steps of inoculating lactic acid bacteria to Galgeuntang, culturing thereof, and fermenting thereof, and a composition for preventing or treating liver toxicity comprising the said fermented Galgeuntang or Galgeuntang. The composition of the present invention has treatment effect on liver toxicity, so that it can be effectively used as a liver function recovering agent or health food for liver function recovery. 113-. (canceled)14. A method for prevention or treatment of liver toxicity comprising the step of administrating a composition comprising either or both of Galgeuntang and lactic acid bacteria fermented Galgeuntang as an active ingredient.15Puerariae radixCinnamomi ramulus. The method according to claim 14 , wherein the Galgeuntang is prepared by hot water extraction of the mixture of medicinal herbs including Galgeun () claim 14 , mahuang claim 14 , ginger claim 14 , jujube claim 14 , licorice claim 14 , peony and gyeji ().16Cinnamomi ramulusPuerariae radix. The method according to claim 14 , wherein the Galgeuntang is prepared by mixing 2-10 parts by weight of mahuang claim 14 , 2-10 parts by weight of ginger claim 14 , 2-10 parts by weight of jujube claim 14 , 1-7 parts by weight of licorice claim 14 , 1-7 parts by weight of peony claim 14 , and 1-7 parts by weight of gyeji () with 12 parts by weight of Galgeun ().17. The method according to claim 14 , wherein the lactic acid bacteria fermented Galgeuntang is prepared by fermenting the Galgeuntang inoculated with lactic acid bacteria.18Bifidobacterium, Lactobacillus, Streptococcus, Leuconostoc, PediococcusLactococcus. The method according to claim 14 , wherein the lactic acid bacteria are selected from the group consisting of claim 14 , and sp. ...

Подробнее
Номер записи: 32
31-10-2013 дата публикации

COMPOSITION COMPRISING CINNAMON EXTRACT

Номер: US20130287872A1
Автор: Beejmohun Vickram, Chapal Nicolas
Принадлежит: DIALPHA

The invention concerns a composition for lowering the glycemic index comprising, or consisting of an alcoholic extract of cinnamon in an amount of at least 10% by weight compared to the total weight of the composition, and optionally a carrier, a food composition comprising a composition for lowering the glycemic index in an amount ranging from 0.1% to 5% by weight compared to the total weight of the food composition, the use of a composition for lowering the glycemic index or of a food composition as a glycemic index lowering agent. 1cinnamomum zeylanicum. Extract of , susceptible of being obtained by the process comprising the following steps:{'i': 'cinnamomum zeylanicum', 'a) contacting dried milled bark with an extraction solvent at a temperature of around 50° C.,'}b) filtering out the solids and collecting alcoholic extract c) washing said solids by stirring with an extraction solventd) filtering out the solids and collecting alcoholic extracte) combining said alcoholic extractsf) removing non-soluble residues by decantation or filtrationg) evaporating the solvents from the combination at a temperature inferior or equal to 50° C.h) recovering a dry extract2. Extract according to claim 1 , characterised in that said extract comprises at least 25% by weight of polyphenols.3. Extract according to claim 1 , characterised in that said extract comprises at least 40% by weight of polyphenols.4. Composition comprising an extract according to any of to .5. Composition according to claim 4 , comprising at least 10% by weight of said extract.6. Food composition comprising 0.05% to 5% by weight of an extract according to any of to .7. Food composition comprising 0.2% to 2% by weight of an extract according to any of to .8. Food composition according to any of or characterised in that it comprises starch.9. Food composition according to claim 8 , characterised in that the ratio extract/starch is of 1/10000 or more.10. Food composition according to claim 8 , characterised in ...

Подробнее
Номер записи: 33
07-11-2013 дата публикации

PTEROSTILBENE AND CURCUMIN COMBINATION FOR TREATMENT OF OXIDATIVE STRESS AND INFLAMMATION

Номер: US20130296440A1
Автор: Bartos Jeremy
Принадлежит: ChromaDex Inc.

A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of curcumin, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to digestive disorders or cancer. A method of treating an individual for an inflammatory disorder is provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a curcumin, and a pharmaceutically acceptable carrier. The combination containing pterostilbene and curcumin is effective for treatment or prevention of oxidative stress, treatment of digestive disorders including inflammatory bowel disease, and/or to reduce or inhibit inflammation, in both animals and in humans. 1. An anti-inflammatory pharmaceutical composition comprising a therapeutically effective amount of pterostilbene , a therapeutically effective amount of curcumin , and a pharmaceutically acceptable carrier.2. The anti-inflammatory pharmaceutical composition of claim 1 , wherein pterostilbene is present in an amount from about 5 mg to about 500 mg claim 1 , and curcumin is present in an amount from about 100 mg to about 2000 mg.3. The anti-inflammatory pharmaceutical composition of claim 1 , wherein pterostilbene is present in an amount from about 50 mg to about 150 mg.4. An anti-inflammatory veterinary composition comprising a therapeutically effective amount of pterostilbene claim 1 , a therapeutically effective amount of curcumin claim 1 , and an acceptable carrier.5. The anti-inflammatory veterinary composition of claim 4 , wherein pterostilbene is present in an amount from about 1 mg to about 1500 mg claim 4 , and curcumin is present in ...

Подробнее
Номер записи: 34
14-11-2013 дата публикации

CURCUMINOID SOLID DISPERSION FORMULATION

Номер: US20130303628A1
Автор: Breitenbach Jörg, Chuah Ai Mey, Das Tapas, Kessler Thomas K., Patel Guarav C., Sathyavageeswaran Shreeram, Schneider Katrin
Принадлежит:

A curcuminoid formulation, comprising a melt-processed solid dispersion product comprising one or more curcuminoids, a nutritionally acceptable thermoplastic polymer, and a phosphatide; providing an improved oral bioavailability compared to non-formulated crystalline curcuminoid. A method for producing said formulation. A nutritional product fortified with said formulation. Said formulation for use in the treatment or prophylaxis of cancer, conditions involving an inflammatory reaction, neurological disorders, cardiovascular disease, pulmonary disease, the formation of cholesterol gallstones, and parasitic infestation. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. A curcuminoid formulation , comprising a melt-processed solid dispersion product comprisinga) one or more curcuminoids,b) a nutritionally acceptable thermoplastic polymer, andc) a phosphatide.17. The curcuminoid formulation of claim 16 , wherein the solid dispersion product additionally comprises a normally solid polyol.18. The curcuminoid formulation of claim 16 , wherein the curcuminoid(s) are present in an essentially non-crystalline state.19. The curcuminoid formulation of claim 16 , wherein the melt-processed solid dispersion product comprisesa) 0.1 to 50% by weight of the curcuminoid(s),b) 20 to 95% by weight of the nutritionally acceptable thermoplastic polymer, andc) 5 to 50% by weight of the phosphatide.20. The curcuminoid formulation of claim 19 , wherein the melt-processed solid dispersion product further comprises 0 to 50% by weight of a normally solid polyol.21. The curcuminoid formulation of claim 16 , wherein the nutritionally acceptable thermoplastic polymer is selected from cellulose derivatives.22. The curcuminoid formulation of claim 16 , wherein the nutritionally acceptable thermoplastic polymer is hydroxypropyl methyl cellulose. ...

Подробнее
Номер записи: 35
05-12-2013 дата публикации

NOVEL HERBAL COMPOSITION FOR THE TREATMENT OF WOUND HEALING, A REGENERATIVE MEDICINE

Номер: US20130323337A1
Автор: Patankar Suresh Balkrishna
Принадлежит:

The present invention discloses a novel, synergistic, effective herbal composition as a regenerative medicine comprising combination therapeutically effective amounts of extracts obtained from and , along with optionally comprising Pig fat in (Til) oil as a base, useful for the treatment of wound healing. The present invention also discloses a process for preparation of said herbal composition. 1. A novel , synergistic , effective herbal composition as a regenerative medicine for the treatment of wound healing comprising ,{'i': 'Curcuma longa', 'extracts of in an amount of about 5 to 15%;'}{'i': 'Glycyrrhiza glabara', 'extracts of in an amount of about 2 to 30%;'}{'i': 'Hamiltonia suaveolens', 'extracts of in an amount of about 2 to 50%;'}{'i': 'Typha angustifolia', 'extracts of in an amount of about 1 to 50%; and'}{'i': 'Azadirachta indica', 'extracts of in an amount of about 0.5 to 30% of the total composition.'}2Sesamum indicum. The herbal composition as claimed in claim 1 , wherein said composition further comprises oil as a base.3Sesamum indicum. The herbal composition as claimed in claim 2 , wherein oil is present in an amount of about 20 to 60% of the total composition.4. The herbal composition as claimed in claim 3 , wherein said composition comprises claim 3 ,{'i': 'Curcuma longa', 'extracts of in an amount of about 7 to 13%;'}{'i': 'Glycyrrhiza glabara', 'extracts of in an amount of about 5 to 20%;'}{'i': 'Hamiltonia suaveolens', 'extracts of in an amount of about 5 to 30%;'}{'i': 'Typha angustifolia', 'extracts of in an amount of about 2 to 40%;'}{'i': 'Azadirachta indica', 'extracts of in an amount of about 1 to 25% and'}{'i': 'Sesamum indicum', 'oil as a base in an amount of about 25 to 55% of the total composition.'}5. The herbal composition as claimed in claim 3 , wherein said composition comprises claim 3 ,{'i': 'Curcuma longa', 'extracts of in an amount of about 10 to 12%;'}{'i': 'Glycyrrhiza glabara', 'extracts of in an amount of about 8 to 15 ...

Подробнее
Номер записи: 36
12-12-2013 дата публикации

METHODS FOR TREATING NEUROLOGICAL DISORDERS USING NUTRIENT COMPOSITIONS

Номер: US20130330428A1
Автор: Geng Lisa
Принадлежит:

Nutrient compositions comprising botanical extracts and methods of their use for treating, inter alia, autism or apraxia and/or ameliorating one or more symptoms thereof are disclosed. The use of such compositions for enhancing cognitive function and/or one or more aspects thereof, or for treating stroke or seizures and/or ameliorating one or more symptoms thereof are also disclosed. 154-. (canceled)55gymnema sylvestre, commiphora mukul, curcuma longa, camellia sinensis, emblica officinalisterminalis chebula.. A method for treating apraxia , autism , speech impairments , traumatic brain injury , seizure disorders , epilepsy , global delays , or ADHD , comprising administering to a patient in need thereof a nutrient composition that ameliorates one or more symptoms of apraxia , autism , speech impairments , traumatic brain injury , seizure disorders , epilepsy , global delays , or ADHD , said nutrient composition comprising an effective amount of a mixture or purified mixture thereof comprising three or more botanical extracts selected from the group of botanicals consisting of , and56. A method according to claim 55 , wherein the nutrient composition is in granular or powder form.57. A method according to claim 56 , wherein the nutrient composition is capable of being administered orally.58. A method according to claim 57 , wherein the nutrient composition is combined with a liquid vehicle for oral consumption by the patient.59. A method according to claim 58 , wherein the liquid vehicle comprises water or milk.60gymnema sylvestre, commiphora mukul, curcuma longa, camellia sinensis, emblica officinalisterminalis chebula,. A method according to claim 55 , wherein the nutrient composition comprises a mixture or purified mixture thereof comprising botanical extracts selected from each of claim 55 , and61cinnamomum verumcapsicum annuum.. A method according to claim 60 , wherein the nutrient composition further comprises or62. A method according to claim 55 , wherein the ...

Подробнее
Номер записи: 37
19-12-2013 дата публикации

Nanomedicines for early nerve repair

Номер: US20130337075A1
Автор: Ji-Xin Cheng
Принадлежит: PURDUE RESEARCH FOUNDATION

The present disclosure describes hydrophobically modified nanoparticles and polymeric nanostructures that can be utilized to for the treatment of neuronal injury or neuronal disease in an affected patient, along with methods of forming and using the nanoparticles and nanostructures. Furthermore, the nanoparticles and nanostructures are designed as “dual action” compositions to treat neuronal injury and neuronal disease via repair of damaged membrane and suppression of intracellular inflammation.

Подробнее
Номер записи: 38
26-12-2013 дата публикации

SUBSTANTIALLY COUMARIN-FREE EXTRACT OF CINNAMON AND ITS PRODUCTION METHOD

Номер: US20130344181A1
Автор: R.W. Deasy Diah Dwi, Sinambela James M., Tjandrawinata Raymond R., Yuliani Veronika
Принадлежит: PT. DEXA MEDICA

A pharmaceutical composition comprising a substantially coumarin-free extract derived from cinnamon. Its production method including some steps: grinding the raw material, extracting raw material from previous step by maceration using a first solvent to obtain crude extract of , fractionating the extracted raw material from previous step through liquid-liquid extraction using a second solvent, wherein the second solvent is immiscible with the first solvent to obtain substantially coumarin-free extract, and optionally drying the substantially coumarin-free extract. 1Cinnamomum burmanii. A process for the preparation of substantially coumarin-free extract derived from which comprises the steps of:{'i': 'Cinnamomum burmanii,', '(a) grinding raw material of'}{'i': 'Cinnamomum burmanii,', '(b) extracting the raw material from step (a) by maceration using a first solvent to obtain crude extract of'}(c) fractionating the extracted raw material from step (b) through liquid-liquid extraction using a second solvent, wherein the second solvent is immiscible with the first solvent to obtain substantially coumarin-free extract, and optionally(d) drying the substantially coumarin-free extract.2. The process according to claim 1 , wherein the first solvent used in step (b) comprises water claim 1 , alcohols claim 1 , acetone or combination thereof.3. The process according to claim 1 , wherein the ratio of the crude extract of step (b) and the second solvent used in step (c) is around 1:1 to 1:2.4. The process according to claim 1 , wherein the content of coumarin in substantially coumarin-free extract has a value of equal or below 0.39 mg coumarin/kg extract.6Cinnamomum burmanii. A pharmaceutical composition or dietary supplement comprising the substantially coumarin-free extract of according to claim 5 , as a single component or in a combination with suitable pharmaceutical excipient(s) for the manufacturing in solid claim 5 , semi-solid claim 5 , or liquid dosage form claim 5 , ...

Подробнее
Номер записи: 39
26-12-2013 дата публикации

NOVEL USE OF PANDURATIN DERIVATIVES OR AN EXTRACT OF BOESENBERGIA PANDURATA FOR PROMOTING MUSCLE MASS GROWTH, FIGHTING FATIGUE, AND ENHANCING EXERCISE PERFORMANCE CAPABILITY

Номер: US20130344182A1
Автор: HWANG JAE-KWAN, Kim Do Un
Принадлежит:

The present invention relates to the novel use of panduratin derivatives or an extract of for enhancing muscle mass growth, fighting fatigue and enhancing exercise performance. A panduratin derivative or a salt thereof or an extract of of the present invention may be used without side effect and has the effect of increasing the expression of PPAR-δ in muscles to increase muscle mass, promoting recovery from fatigue and increase mobility, thereby improving exercise performance. 1. A composition for enhancing exercise performance comprising a panduratin derivative or a salt thereof as an active ingredient.3Boesenbergia pandurata.. The composition for enhancing exercise performance of claim 1 , wherein the panduratin derivative is extracted from4Boesenbergia pandurata. A composition for enhancing exercise performance comprising an extract of as an active ingredient.5. The composition for enhancing exercise performance of any one of to claim 1 , wherein the composition is a pharmaceutical composition or a food composition.6. A composition enhancing muscle mass growth comprising a panduratin derivative or a salt thereof as an active ingredient.7Boesenbergia pandurata. A composition enhancing muscle mass growth comprising an extract of as an active ingredient.8. An anti-fatigue composition comprising a panduratin derivative or a salt thereof as an active ingredient.9Boesenbergia pandurata. An anti-fatigue composition comprising an extract of as an active ingredient.10. A method for enhancing exercise performance comprising administering an effective amount of a panduratin derivative or a salt thereof to a subject in need thereof.11. Use of a panduratin derivative or a salt thereof for preparing an agent for enhancing exercise performance.12Boesenbergia pandurata. A method for enhancing exercise performance comprising administering an effective amount of an extract of to a subject in need thereof.13Boesenbergia pandurata. Use of an extract of for preparing an agent for ...

Подробнее
Номер записи: 40
26-12-2013 дата публикации

NOVEL COMPOUND ISOLATED FROM KAEMPFERIA PANDURATA ROXB AND USE THEREOF AS ANTIVIRAL AGENT

Номер: US20130344183A1
Автор: Cho Sang Buem, Kim Soo Ki, Lee Jun Hyeong, Moon Hyung In, Paik Hyun Dong, Seo Sang Heui
Принадлежит: KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP.

The present invention relates to a novel compound isolated from Roxb and the use thereof as an antiviral agent. The compound isolated from Roxb shows the ability to inhibit highly pathogenic virus, and thus is a promising candidate for an antiviral agent. 1. (canceled)3Kaempferia pandurataKaempferia pandurata. A method of obtaining the compound of from Roxb , the method comprising the steps of: treating Roxb with an organic solvent to obtain an organic solvent extract; and obtaining the compound of from the organic solvent extract.4. The method of claim 3 , wherein the organic solvent is a Cto Calcohol.5. The method of claim 4 , wherein the alcohol is butanol.6. A pharmaceutical composition for preventing or treating viral disease claim 2 , comprising the compound of claim 2 , or a pharmaceutically acceptable salt thereof.7. The pharmaceutical composition of claim 6 , wherein the viral disease is avian influenza viral disease.8. The pharmaceutical composition of claim 7 , wherein the avian influenza virus is H5N1-serotype avian influenza virus.9Kaempferia pandurata. A feed composition for preventing or treating viral disease claim 2 , comprising the compound of claim 2 , or a butanol extract of Roxb.10. The feed composition of claim 9 , wherein the viral disease is avian influenza virus.11. The feed composition of claim 10 , wherein the avian influenza virus is H5N1-serotype avian influenza virus.12. A method for preventing or treating viral disease claim 2 , comprising a step of administering an effective amount of the compound of claim 2 , or a pharmaceutically acceptable salt thereof to a subject in need of prevention or treatment of viral disease.13. The method of claim 12 , wherein the viral disease is avian influenza viral disease.14. The method of claim 13 , wherein the avian influenza virus is H5N1-serotype avian influenza virus.15Kaempferia pandurata. Use of the compound of claim 2 , or a butanol extract of Roxb in preparation of a pharmaceutical ...

Подробнее
Номер записи: 41
09-01-2014 дата публикации

Curcuminoid composition with enhanced bioavailability and a process for its preparation

Номер: US20140010903A1
Автор: Madhavamenon Krishnakumar Illathu, PAULOSE MALIAKEL Balu
Принадлежит:

The invention relates to a curcuminoid composition with enhanced bioavailability derived from fresh turmeric rhizomes and a process for its preparation. 1. A curcuminoid composition obtained from fresh turmeric rhizomes comprising:a. 2 to 10% curcuminoids,b. 5 to 20% proteins,c. 50 to 75% carbohydrates,d. 10 to 20% dietary fiber ande. 1 to 5% of natural oils (hexane extractable),wherein each of the component is naturally derived from the fresh turmeric rhizome.2. The curcuminoid composition as claimed in claim 1 , wherein the curcuminoid component comprises of curcumin claim 1 , demethoxycurcumin claim 1 , and bisdemethoxycurcumin wherein the percentage of curcumin ranges between 50-78% claim 1 , the ratio of demethoxycurcumin ranges between 10 to 22% claim 1 , and the ratio of bisdemethoxycurcumin ranges between 5 to 24%.3Curcuma longa. The curcumnoid composition as claimed in claim 1 , wherein the composition is obtained from a fresh rhizome of L.4. The curcuminoid composition as claimed in claim 1 , wherein the percentage of curcuminoids ranges between 3 to 8% claim 1 , percentage of proteins ranges between 10 to 16% claim 1 , the percentage of carbohydrates ranges between 60 to 70% claim 1 , the percentage of dietary fiber ranges between 12 to 18% and the percentage of fixed oils is less than 3%.5. A process of making a curcuminoid composition as claimed in comprising the steps of:a. providing fresh rhizomes of turmeric,b. optionally treating the rhizomes with an enzyme,c. extracting the fresh juice from the rhizomes,d. drying the extracted juice to yield a concentrate.6Curcuma longa.. The process as claimed in claim 5 , wherein the rhizomes are selected from the species of7. The process as claimed in claim 5 , wherein the curcuminoid content in the fresh rhizome ranges from 3 to 12%.8. The process as claimed in claim 5 , wherein the extraction process in step b) can be aided with the help of ultrasonication or microwave to result maximum extractability for the ...

Подробнее
Номер записи: 42
23-01-2014 дата публикации

HERBAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASES AND IMPROVING MEMORY IMPAIRMENT

Номер: US20140023677A1
Автор: Kim Dong Sik, Kim Seon Hee, Lee Doo Suk
Принадлежит: VIROMED CO., LTD.

The present invention relates to a composition for preventing or treating neurological diseases including an extract of fruit, red sage and as an active ingredient. The composition of the present disclosure has a superior effect of inhibiting the activity of acetylcholinesterase (AChE), which hydrolyzes the neurotransmitter acetylcholine directly involved in impairment of cognitive function. In addition, the composition of the present disclosure is safe for the human body since the biologically safe extract of fruit, red sage and is used as the active ingredient. 112-. (canceled)13Euphoria longanGastrodia elata. A method for preventing or treating neurological diseases , comprising: administering to a subject a composition comprising an extract of a mixture of fruit , red sage and as an active ingredient.14. The method according to claim 13 , wherein the composition is a pharmaceutical composition or food composition.15Euphoria longanGastrodia elata. A method for improving brain or cognitive function claim 13 , comprising: administering to a subject a composition comprising an extract of a mixture of fruit claim 13 , red sage and as an active ingredient.16. The method of claim 13 , wherein the neurological disease is selected from a group consisting of degenerative nerve disease and mental disorder.17. The method of claim 16 , wherein the degenerative nerve disease is a neurological disease selected from a group consisting of dementia claim 16 , Alzheimer's disease claim 16 , Huntington's disease claim 16 , Parkinson's disease and amyotrophic lateral sclerosis.18. The method of claim 16 , wherein the mental disorder is selected from a group consisting of depression claim 16 , schizophrenia and posttraumatic stress disorder.19. The method of claim 15 , wherein the brain or cognitive function is learning ability claim 15 , memory or concentration.20. The method of claim 19 , wherein the method is for improving memory impairment.21ophiopogonCnidium officinale, Angelica ...

Подробнее
Номер записи: 43
30-01-2014 дата публикации

PEST-IMPERVIOUS PACKAGING MATERIAL AND PEST-CONTROL COMPOSITION

Номер: US20140031431A1
Автор: Angel Sam, Dias Refael, Finkelman Simcha, Mansur Fadel, NAVARRO Shlomo, Rindner Miriam, Zehavi Dov
Принадлежит:

A composition-of-matter comprising a substance usable in producing packaging material and at least one compound selected from the group consisting of ar-turmerone, a sesquiterpene alcohol and a turmeric oleoresin solid residue. 1. A composition-of-matter comprising a packaging material and a pest control composition comprising at least 10% by weight of a sesquiterpene alcohol , said pest control composition being incorporated in or on said packaging material.2. The composition-of-matter of claim 1 , wherein said packaging material is coated with a laminate including said pest control composition.3. The composition-of-matter of claim 1 , wherein said packaging material is impregnated with said pest control composition.4. The composition-of-matter of claim 1 , wherein said packaging material comprises a margin for welding or gluing said packaging material claim 1 , said margin being coated with a coating substance including said pest control composition.5. The composition-of-matter of claim 1 , wherein said sesquiterpene alcohol is selected from the group consisting of hinesol claim 1 , agarospirol claim 1 , valerianol claim 1 , β-bisabolol claim 1 , α-bisabolol claim 1 , γ-eudesmol claim 1 , ar-turmerol claim 1 , α-copaen-11-ol claim 1 , [E]-nerolidol and gossonorol claim 1 , and any combination thereof.6. The composition-of-matter of claim 1 , wherein said pest control composition further comprises a turmeric oleoresin solid residue.7. The composition-of-matter of claim 1 , wherein said pest control composition further comprises ar-turmerone.8. The composition-of-matter of claim 6 , wherein said pest control composition further comprises ar-turmerone.9. A packaged product comprising a product contained within a packaging material modified to include a pest control composition comprising at least 10% by weight of a sesquiterpene alcohol.10. The packaged product of claim 9 , wherein said packaging material is impregnated or coated with said pest control composition.11 ...

Подробнее
Номер записи: 44
06-02-2014 дата публикации

ADDITIVES FOR ANIMAL FOOD

Номер: US20140037698A1
Автор: PABLOS PÉREZ Enrique
Принадлежит: NOREL, S.A

The present invention relates to the combination of organic acid salts with at least one active ingredient of plant origin, preferably essential oils, partially protected with vegetable fats and/or oils, which prevent these active ingredients from being digested by stomach enzymes during the digestive process. The sodium salts of short-chain acids, preferably salts of butyric, acid are preferred. The preferred essential oils are ginger, piperine, oregano, garlic, thymol, carvacrol, cinnamaldehyde and/or any combinations thereof. The combination of organic acid salts and the essential oils protected with vegetable fats and/or oils, are used as powerful promoters or stimulants for animal growth, as organic bactericides against pathogenic bacteria present in said animals and as modulators of immune response thereof. 1. Additive for animal feed comprising the combination of a salt of an organic acid with at least one active ingredient of plant origin , this combination partially coated with vegetable oils and/or fats.2. The additive for animal feed according to wherein the organic acid are selected from the group consisting of butyric claim 1 , propionic claim 1 , formic claim 1 , lactic claim 1 , citric claim 1 , lauric claim 1 , capric claim 1 , caprylic claim 1 , caproic claim 1 , and acetic.3. The additive for animal feed according to wherein the the salt is selected from the group consisting of sodium claim 1 , calcium claim 1 , cupric and potassium.4. The additive for animal feed according to claim 1 , wherein the salt of the organic acid is preferably the sodium salt of butyric acid.5. The additive for animal feed according to claim 1 , wherein the salt of the organic acid is preferably in a proportion of 30-70% of the wet weight.6. The additive for animal feed according to wherein the active ingredients of plant origin comprise essential oils selected from the group consisting of ginger claim 1 , piperine claim 1 , oregano claim 1 , thymol claim 1 , carvacrol ...

Подробнее
Номер записи: 45
06-02-2014 дата публикации

COMPOSITIONS FOR THE SYMPTOMATIC RELIEF OF STOMACH PAIN OR GASTROOESOPHAGEAL REFLUX

Номер: US20140037730A1
Автор: GAGO DE SANTOS ANGEL MANUEL
Принадлежит:

Compositions useful for relieving the symptoms commonly known as stomach acidity, heartburn or, more technically, esophageal reflux (GERD), that comprise a fatty acid and a plant extract. These compositions have been tried in patients with clinical records of previous diagnosis of GERD, chronic heartburn, or esophagitis, with a high degree of success. 1. A method for re-establishment of digestive homeostasis affected by peptic acid disorders caused by damage to the gastric mucosa or digestive epithelium which comprises administering to a subject who has been diagnosed to be in need of a treatment therefor an effective amount of a composition comprising:{'sub': 1', '10, 'at least one C-Cfatty acid from the group that consists of butyric acid or isobutyric acid, alone or combined, or their alkali or alkaline-earth metal salts, or a glycerol ester thereof, and'}at least one plant extract from the alliaceae family.2. The method of claim 1 , wherein the plant extract from the alliaceae family is a garlic extract.3. The method of claim 2 , wherein the garlic extract is powdered claim 2 , non-deodorized claim 2 , dry extract.4. The method of claim 1 , wherein the alkali or a1kaline-earth metal salt of at the least one C1-C10 fatty acid is a sodium claim 1 , calcium or potassium salt thereof.5. The method of claim 4 , wherein the sodium claim 4 , calcium or potassium salt of the C1-C10 fatty acid is sodium butyrate.6. The method of claim 4 , wherein the sodium claim 4 , calcium or potassium salt of the C1-C10 fatty acid is buffered with a buffer selected front phosphate salts and carbonate salts.7. The method of claim 1 , wherein the glycerol ester of at least one C1-C10 fatty acid is a triglyceride thereof.8curcuma. The method of claim 1 , wherein a plant extract is also administered to said subject.9. The method of claim 1 , wherein the composition further comprises at least one excipient selected from the group consisting of vehiculizing agents claim 1 , thinners claim 1 ...

Подробнее
Номер записи: 46
13-02-2014 дата публикации

NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE EFFECT

Номер: US20140045904A1
Автор: KUHRTS Eric Hauser
Принадлежит:

Compositions and methods for reducing the flushing effect (cutaneous erythema) of niacin and for treating hyper lipemia and elevated triglycerides, comprising a prenylflavonoid, such as xanthohumol, and niacin (nicotinic acid or Vitamin B3). 1. A pharmaceutical composition with hypolipemic or hypotryglyceridemic amounts of niacin having reduced capacity to provoke a flushing reaction in a subject , comprising a hypolipemic or hypotryglyceridemic amount of niacin , and a prenylflavonoid.2. The composition of claim 1 , wherein the prenylflavonoid is a prenylflavonone.3. The composition of claim 1 , wherein the prenylflavonoid is a prenylchalcone.4. The composition of claim 1 , wherein the prenylflavonoid is selected from the group consisting of xanthohumol claim 1 , xanthogalenol claim 1 , desmethylxanthohumol (2′ claim 1 ,4′ claim 1 ,6′ claim 1 ,4-tetrahydrooxy-3-C-prenylchalcone) claim 1 , 2′ claim 1 ,4′ claim 1 ,6′ claim 1 ,4-tetrahydrooxy-3′-C-geranylchalcone claim 1 , dehydrocycloxanthohumol claim 1 , dehydrocycloxanthohumol hydrate claim 1 , 5′-prenylxanthohumol claim 1 , tetrahydroxanthohumol claim 1 , 4′-O-5′-C-diprenylxanthohumol claim 1 , chalconaringenin claim 1 , isoxanthohumol claim 1 , 6-prenylnaringenin claim 1 , 8-prenylnaringenin claim 1 , 6 claim 1 ,8-diprenylnaringenin claim 1 , 4′ claim 1 ,6′-dimethoxy-2′ claim 1 ,4-dihydroxychalcone claim 1 , 4′-O-methylxanthohumol claim 1 , 6-geranylnaringenin claim 1 , 8-geranylnaringenin claim 1 , metabolites thereof claim 1 , derivatives thereof claim 1 , and combinations thereof.5. The composition of claim 1 , wherein the prenylflavonoid is xanthohumol claim 1 , a xanthohumol metabolite claim 1 , or a xanthohumol derivative.6. The composition of claim 5 , wherein the composition includes from 0.5 mg to 1000 mg of xanthohumol.7. The composition of claim 5 , wherein the composition includes from 5 mg to 250 mg of xanthohumol.8. The composition of claim 5 , wherein the composition includes from 10 mg to 50 mg of ...

Подробнее
Номер записи: 47
27-02-2014 дата публикации

COMPOSITIONS COMPRISING EXTRACTS OR FRACTIONS DERIVED FROM ANNONA SQUAMOSA FOR THE PREVENTION, TREATMENT OR CONTROL OF INFLAMMATORY AND METABOLIC DISORDERS

Номер: US20140056987A1
Автор: ALLURI Venkata Krishna Raju, Bhupthiraju Kiran, GOKARAJU Ganga Raju, GOKARAJU Rama Raju, GOKARAJU Venkata Kanaka Ranga Raju, GOLAKOTI Trimurtulu, SENGUPTA Krishanu
Принадлежит: LAILA NUTRACEUTICALS

The invention discloses synergistic composition comprising at least one derived component standardized to acetogenin compound(s) having α,β-unsaturated-γ-methyl-γ-lactone moiety in combination with at least one biologically active ingredient derived from plants, animals or microorganisms such as vitamins, amino acids, minerals, fibers, various plant and herbal extracts for the prevention, treatment, inhibition or controlling inflammation and/or metabolic disorders and other associated or related diseases. The invention further discloses the method of treating inflammation and/or metabolic disorders and other associated or related diseases. 1Annona squamosaBoswellia serrataAndrographis paniculataTerminalia chebulaCurcuma longa. Synergistic composition comprising a biologically effective extract or fraction of , said biologically effective extract comprising from 0.01 to 30% by weight of at least one compound selected from the group consisting of acetogenins having terminal α ,β-unsaturated-γ-methyl-γ-lactone moiety in combination with at least one biologically active ingredient selected from the group consisting of vitamin A , vitamin B 12 , vitamins C , Vitamin D , vitamin E , krill oil , omega-3-fatty acid , selenium , extract standardized to Boswellic acids , extract , extract , extract , magnesium , selenomethionine , selenocysteine , methylselenocycteine and mixtures thereof.3. The herbal composition according to claim 1 , wherein said acetogenins are selected from the group consisting of squamocin C (LI12103) claim 1 , isosquamocin (LI12132) claim 1 , Dieposabadelin (LI12109) claim 1 , squamostatin D (LI12106) claim 1 , squamocin L (LI12107) claim 1 , squamocin J (LI12111) claim 1 , squamocin G (LI12105) claim 1 , 10-hydroxyasimicin (LI12110); compound LI12104 claim 1 , compound LI12114 claim 1 , compound LI12115 claim 1 , compound LI12112 claim 1 , compound LI12113 claim 1 , compound LI12116 and compound LI12117.4. The compositions as claimed claim 1 , wherein ...

Подробнее
Номер записи: 48
06-03-2014 дата публикации

CURCUMIN-ER, A LIPOSOMAL-PLGA SUSTAINED RELEASE NANOCURCUMIN FOR MINIMIZING QT PROLONGATION FOR CANCER THERAPY

Номер: US20140065061A1
Автор: Helson Lawrence, Mukerjee Anindita, Ranjan Amalendu Prakash, Vishwanatha Jamboor K.
Принадлежит:

The present invention includes compositions and methods of making a nanoparticle composition comprising a polymeric core comprising one or more polymers and one or more active agents, and at least one layer of one or more lipids on the surface of the polymeric core; more specifically, the invention relates to the use of curcumin within such a lipid-polymer nanoparticle formulation for minimizing QT prolongation associated with curcumin in treatment of cancer. 1. A composition for treating cancer comprising:a polymeric nanoparticle core comprising one or more polymers and at least one of curcumin or curcuminoids; andat least one layer of one or more lipids on the surface of the polymeric core, wherein the at least one of the curcumin or curcuminoids nanoparticles, wherein the composition does not cause QT prolongation when provided to a subject.2. The nanoparticle composition of claim 1 , wherein the one or more polymers comprise at least one of poly(lactic-co-glycolic acid) (PLGA) claim 1 , poly(lactic acid) claim 1 , polylactide (PLA) claim 1 , or poly-L-lactide-co-ε-caprolactone (PLCL).3. The nanoparticle composition of claim 1 , wherein the composition further comprises an active agent selected from at least one of an anti-cancer drug claim 1 , an antibiotic claim 1 , an antiviral claim 1 , an antifungal claim 1 , an antihelminthic claim 1 , a nutrient claim 1 , a small molecule claim 1 , a siRNA claim 1 , an antioxidant claim 1 , and an antibody claim 1 , or a conventional radioisotope.4. The nanoparticle composition of claim 1 , wherein the one or more lipids comprise at least one of dimyristoyl phosphatidylcholine (DMPC) claim 1 , dimyristoyl phosphatidylglycerol (DMPG) claim 1 , 1 claim 1 ,2-dioctadecanoyl-sn-glycero-3-phosphoethanolamine (DSPE) claim 1 ,1 claim 1 ,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol) (DSPE-PEG) claim 1 , DMPE PEG Maleimide claim 1 , Lecithin claim 1 , cholesterol claim 1 , 1 claim 1 ,2-dimyristoyl-sn- ...

Подробнее
Номер записи: 49
06-03-2014 дата публикации

SPROUTED CEREAL, METHOD FOR MANUFACTURING SAME, FOOD PRODUCT CONTAINING SAME, AND BDNF PRODUCTION ACCELERATOR

Номер: US20140065249A1
Автор: YANAMOTO Hiroji
Принадлежит:

The invention relates to a novel technique for germinating a sproutable food such as rice, other types of cereals, or seeds. Provided is a novel germination technique capable of increasing a content of glutamate, accelerating an enrichment of gamma-aminobutyric acid, and exerting excellent functionality for the body, and a novel functional food material or pharmaceutical agent. A sprouted cereal is produced by soaking the cereal in a soaking solution prepared by addition of at least one carbonate selected from alkali metal carbonate, and alkaline earth metal carbonate to water to make the cereal absorb the soaking solution, followed by allowing the cereal to germinate under predetermined conditions. 123.-. (canceled)24. A sprouted cereal , produced by soaking the cereal in a soaking solution having a hydrogen carbonate ion concentration of 0.012 to 0.12 mol/l prepared by addition of at least one carbonate selected from alkali metal carbonate , alkaline earth metal carbonate , and ammonia carbonate to water to make the cereal absorb the soaking solution , followed by allowing the cereal to germinate under predetermined conditions.25. The sprouted cereal according to claim 24 , whereinpH of the soaking solution ranges from 8.0 to 10.0.26. The sprouted cereal according to claim 24 , whereinthe carbonate is sodium carbonate, sodium bicarbonate, or sesquisodium carbonate.27. The sprouted cereal according to claim 24 , whereina glutamate content of the sprouted cereal is 1.1 to 2.3 times greater than a glutamate content of a sprouted cereal germinated under the same conditions except that the latter is germinated without addition of the carbonate, when measured by a reference measurement method.28. The sprouted cereal according to claim 24 , whereinthe cereal is brown rice, and a glutamate content of the brown rice is 25 to 100 mg/100 g when measured by a reference measurement method.29. The sprouted cereal according to claim 24 , whereina hydrogen carbonate ion ...

Подробнее
Номер записи: 50
06-03-2014 дата публикации

Use of xanthohumol and/or isoxanthohumol as an agent for preventing and/or combating liver diseases

Номер: US20140066519A1
Автор: Claus Hellerbrand
Принадлежит: Flaxan GmbH and Co KG

Method for the prevention and/or control of liver diseases, such as non-alcoholic steatohepatitis (NASH) even when eating a high fat diet. Prevention of NASH can be accomplished by preventing the liver from becoming a fatty liver even when eating a high fat diet by providing xanthohumol as a supplement to the high fat diet.

Подробнее
Номер записи: 51
20-03-2014 дата публикации

CINNAMOMUM BURMANII EXTRACT, EXTRACTION PROCESS AND ITS USE AS PROTON PUMP DOWN-REGULATOR, ENZYME INHIBITOR, AND MUCOPROTECTOR

Номер: US20140079820A1
Автор: ARIFIN POPPY FIRZANI, R.W. Deasy Diah Dwi, Sinambela James M., Tjandrawinata Raymond R., Yuliani Veronika
Принадлежит: PT. DEXA MEDICA

Extract and/or fraction from (DLBS2411) related to its extraction method and its biological activities show activities as antiulcer by conferring mucoprotection and down-regulating H/K ATPase. Treatment with DLBS2411 decreases the H/K ATPase mRNA level in HEK 293 and gastric parietal cells. In addition, DLBS2411 inhibits activity of H/K ATPase gastric enzyme wherein pH influences this inhibition mechanism. DLBS2411 also has characteristic as antioxidant which is shown by the increase of reducing power as the given dosage increases. 1Cinnamomum burmanii. An extract comprising , and/or its fraction or its group of compound derived therefrom , in pharmaceutical preparation , as a single active ingredient or in combination , in an amount or dose that is effective as antiulcer.2. Extract and/or fraction according to claim 1 , whereby said extract and/or fraction has the activity as down-regulator of H/K ATPase proton pump.3. Extract and/or fraction according to claim 1 , whereby said extract and/or fraction has the activity as inhibitor of H/K ATPase enzyme.4. Extract and/or fraction according to claim 1 , whereby said extract and/or fraction has the activity as mucoprotector.5. Extract and/or fraction according to claim 1 , whereby such extract is obtained by the process comprising the steps of:(a) extraction using hot water at temperature of 50-100° C.,(b) liquid liquid extraction using organic solvent to obtain water fraction.6. Extract and/or fraction according to claim 5 , whereby the process further comprises the step of repetition of step (b) to optimize the collection of water fraction.7. Extract and/or fraction according to claim 5 , whereby the organic solvent(s) at step (b) is selected from the group consisting of chloroform claim 5 , dichloromethane claim 5 , hexane claim 5 , ethyl acetate and butanol.8. A pharmaceutical composition comprising said extract and/or fraction according to claim 1 , as a single active ingredient or in combination claim 1 , and ...

Подробнее
Номер записи: 52
20-03-2014 дата публикации

FOOD PRODUCT COMPRISING RYE

Номер: US20140079833A1
Автор: BJORCK Inger, Nilsson Anne, Nyman Margareta, OSTMAN Elin, Rosen Liza
Принадлежит: RYEFACTOR AB

A rye extract as well as food compositions including the extract. The use of the extract for the manufacture of a food composition, a dosage product, a pharmaceutical or a medicament. The extract is useful as a food composition, dosage product, pharmaceutical or medicament for the treatment, controlling or prevention of diseases or conditions related to metabolic syndrome, diabetes or obesity or in the promotion of satiety, weight loss or maintenance of desired body weight. 1. A method of making a rye extract comprising the steps of:a.) providing a rye material, such as rye kernels and/or plant material from rye such as whole straw;b.) milling said rye material;c.) dispersing said milled rye material in a liquid;d.) incubating said dispersion of step c.);e.) optionally solubilizing and/or disintegrating aggregates in the dispersion from step d.);f.) optionally heating the solubilized dispersion from step e.);g.) optionally adding an alcohol suitable for human consumption, such as ethanol to reach a concentration of from 20% to 100% and allowing precipitation to take place;h.) optionally filtering away the precipitate from step g.);i.) recovering the liquid phase, for example by centrifuging and recovering the liquid supernatant; andj.) optionally concentrating the liquid phase from i.).2. The method according to wherein a fermentation step k.) is inserted after step c.) claim 1 , wherein one or more probiotic is added.3. The rye extract obtainable by the method of .4. The rye extract obtained by the method of .5. A rye extract according to comprising Fructan (DP 1-10) claim 1 , Fructan (DP=10-20) claim 1 , Arabinoxylans (DP>10) claim 1 , Non-cellulosic beta-glucans (DP>100) and Raffinose (DP=3-5) claim 1 , as well as Arabinoxylan oligosaccharides (DP=2-10) claim 1 , mannoproteins and Mellobiose (DP=2).6. The method according to wherein the rye material is selected from the group consisting of rye variety Visello and Picasso or a combination thereof.7. A supplemented ...

Подробнее
Номер записи: 53
27-03-2014 дата публикации

GOOD HEALTHY CELLS FOUND IN PROTEINS, THEIR APPLICATIONS, AND PROCESS OF MAKING A MEDIUM TO HARVEST THE CELLS

Номер: US20140086881A1
Автор: Hoang Kieu
Принадлежит:

GOOD HEALTHY DRAGON, SNAKE, DIFFERENT SIZE DOUBLE RINGS, LIGHTNING, SQUARE PIXEL, BEAMING RAYS, RECONSTRUCTION BACKGROUND, FACET, CRATER, YELLOW, LEER CELLS were found in New Proteins (among them 27 new ones and their sequences (Under a different patent application) or in the existing discovered proteins and their applications. The process of making the medium derived from any source to harvest any cell—named KH cells—KH cells are good healthy cells in which the RNA synthesizes good proteins that: 1—Send signal to the DAMAGED, SICK, AND BAD CELLS that triggers that synthesis of good proteins that transform these cells to become GOOD healthy cells. 2—Send signal to the other currently undamaged cells to synthesis of good proteins to protect them from being DAMAGED, INFECTED and PRONE to DNA and other cellular alterations. 3—Send signal to the body to produce new cells that are healthy and forbid them from being affected by intra- and extracellular damaging signals to increase the protein yield for the application of the cell expression of human healthcare, animal healthcare and plant healthcare including fertilizer and maximize production of medicine, food, fruit, juice, meat, seafood and plants. 1. A method of introduction of good healthy cells selected from the group consisting of DRAGON CELLS , SNAKE CELLS , GOOD HEALTHY DOUBLE RINGS DIFFERENT SIZE CELLs , GOOD HEALTHY LIGHTNING CELLs , GOOD HEALTHY SQUARE PIXEL CELLs , BEAMING RAYS CELLs , GOOD HEALTHY RECONSTRUCTION BACKGROUND CELLs , GOOD HEALTHY FACET CELLs , GOOD HEALTHY CRATER CELLs , GOOD HEALTHY YELLOW CELLs , GOOD HEALTHY LEER CELLs , containing Good Proteins to send signal to DNA of sick , bad , damaged cells to transform RNA to synthesize Good Protein to cure diseases , viruses infections , Bacteria Infection , Auto immune disease , Neurological disorder , all type of 150 solid and blood cancers , coagulation , Diabetic , Inhibitor , Immune deficiency.2. The method of claim 1 , wherein the good healthy ...

Подробнее
Номер записи: 54
03-04-2014 дата публикации

Composition to Enhance the Bioavailability of Curcumin

Номер: US20140093594A1
Автор: Antony Benny
Принадлежит: ARJUNA NATURAL EXTRACTS, LTD.

A composition having a curcuminoid and an essential oil of turmeric. A composition having a curcuminoid and an essential oil of turmeric, wherein the essential oil is present in an amount sufficient to cause an enhancement of bioavailability of curcumin when the composition is administered to a human as compared to bioavailability of curcumin obtained upon administration of a composition prepared without adding essential oil to the curcuminoid. A method to prepare a composition having a curcuminoid and an essential oil of turmeric. 1. A gelatin capsule comprising a composition , the composition comprising a curcuminoid mixture and an essential oil of turmeric , the composition prepared by the method comprising:suspending the curcuminoid mixture in water to form a suspension;adding the essential oil of turmeric to the suspension to form a second mixture;homogenizing the second mixture to obtain a fine slurry; anddrying the fine slurry under heat and vacuum to form a uniform blend of the composition comprising the curcuminoid and the essential oil of turmeric,wherein the curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin, and wherein the essential oil of turmeric comprises about 45% ar-turmerone.2. The gelatin capsule of claim 1 , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric ranges from about 3:1 to about 95:5.3. The gelatin capsule of claim 1 , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric is about 10:1.4. The gelatin capsule of claim 1 , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric is about 85:15.5. The gelatin capsule of claim 1 , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric is about 92:8.6. The gelatin capsule of claim 1 , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric is about 95:5.7. A gelatin capsule ...

Подробнее
Номер записи: 55
10-04-2014 дата публикации

Formulation of Curcumin With Enhanced Bioavailability of Curcumin and Method of Preparation and Treatment Thereof

Номер: US20140099390A1
Автор: Antony Benny
Принадлежит:

Disclosure provides a formulation of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin and to augment the biological activity of curcumin, wherein curcumin is the main constituent of curcuminoid and wherein Ar-turmerone is the main constituent of the essential oil of turmeric. An application of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin for oral supplementation against a variety of diseases and method of doing the same is provided. 1. A method of treating rheumatoid arthritis comprising administering a composition of a curcuminoid mixture and added essential oil of turmeric , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric ranges from about 1:3 to about 99:1 , wherein the curcuminoid mixture comprises curcumin , demethoxycurcumin and bisdemethoxycurcumin , and wherein the essential oil of turmeric comprises ar-turmerone.2. A method of reducing visual analogue scale for pain comprising administering a composition of a curcuminoid mixture and added essential oil of turmeric , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric ranges from about 1:3 to about 99:1 , wherein the curcuminoid mixture comprises curcumin , demethoxycurcumin and bisdemethoxycurcumin , and wherein the essential oil of turmeric comprises ar-turmerone.3. A method of decreasing disease activity score comprising administering a composition of a curcuminoid mixture and added essential oil of turmeric , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric ranges from about 1:3 to about 99:1 , wherein the curcuminoid mixture comprises curcumin , demethoxycurcumin and bisdemethoxycurcumin , and wherein the essential oil of turmeric comprises ar-turmerone.4. A method of improving patient response to ACR criteria comprising administering a composition of a curcuminoid mixture and added essential oil of ...

Подробнее
Номер записи: 56
10-04-2014 дата публикации

SYNERGISTIC SALIVATION AGENTS

Номер: US20140099391A1
Автор: Green Carter B., Manley Charles, Spence David J.
Принадлежит: TAKASAGO INTERNATIONAL CORP. (USA)

Provides is a salivation cocktail that comprises a food acid and a tingling sensate. The combination of a food acid and a tingling sensate has been found to synergistically increase salivation. 1. A salivation cocktail composition consisting essentially of (a) at least one food acid and (b) at least one tingling sensate.2. The salivation cocktail of claim 1 , wherein the tingling sensate is selected from spilanthol claim 1 , sanshool claim 1 , hydroxyl α-sanshool claim 1 , hydroxy .beta.-sanshool claim 1 , hydroxyl γ-sanshool claim 1 , sanshool-I claim 1 , sanshool II claim 1 , sanshoamide claim 1 , japanese pepper extract claim 1 , black pepper extract claim 1 , chavicine claim 1 , piperine claim 1 , echinacea extract claim 1 , northern prickly ash extract claim 1 , Nepalese spice timer extract claim 1 , red pepper oleoresin claim 1 , 4-(1-menthoxymethyl)-2-phenyl-1 claim 1 ,3-dioxolane claim 1 , n-isobutyldeca-trans-2-trans-4-dienamide claim 1 , n-cyclopropyl claim 1 , trans-2-cis-6-nonadienamide claim 1 , n-ethyl trans-2-cis-6-nonadienamide and jambu oleoresin.3. The salivation cocktail composition of claim 2 , wherein the tingling sensate is selected from spilanthol claim 2 , sanshool and α-hydroxysanshool.4. The salivation cocktail composition of claim 3 , wherein the tingling sensate is spilanthol.5. The salivation cocktail composition of claim 4 , wherein the spilanthol is obtained from jambu oleoresin.8. The salivation cocktail composition of claim 2 , wherein the food acid is selected from acetic acid claim 2 , adipic acid claim 2 , aspartic acid claim 2 , benzoic acid claim 2 , caffeotannic acid. citric acid claim 2 , iso-citric acid claim 2 , citramalic acid claim 2 , formic acid claim 2 , fumaric acid claim 2 , galacturonic acid claim 2 , glucuronic acid claim 2 , glyceric acid claim 2 , glycolic acid claim 2 , ketoglutaric acid claim 2 , a-ketoglutaric acid claim 2 , lactic acid claim 2 , lactoisocitric acid claim 2 , malic acid claim 2 , oxalacetic ...

Подробнее
Номер записи: 57
07-01-2016 дата публикации

CURCUMIN SOLID LIPID PARTICLES AND METHODS FOR THEIR PREPARATION AND USE

Номер: US20160000714A1
Автор: Diorio Christopher, Lokhnauth John
Принадлежит: Capsugel Belgium NV

Solid lipid particles comprising a lipid hydrophobic matrix and from about 5 wt. % to about 30 wt. % of curcumin, and methods of making and treatment thereof. 1. Solid lipid particles comprising: a lipid hydrophobic matrix; and from about 5 wt. % to about 30 wt. % of curcumin , wherein said lipid hydrophobic matrix is substantially free of water and wherein said solid lipid particles have an average particle size diameter ranging from 100 μm to 1500 μm.2. The solid lipid particles according to claim 1 , wherein the lipid hydrophobic matrix has a melting point ranging from about 15° C. to about 85° C.3. The solid lipid particles according to claim 1 , wherein the lipid hydrophobic matrix has a melting point ranging from about 30° C. to about 45° C.4. The solid lipid particles according to claim 1 , wherein the lipid hydrophobic matrix optionally contains at least one surfactant.5. The solid lipid particles according to claim 1 , wherein the curcumin has an average particle size diameter ranging from about 0.1 μm to about 10 μm.6. (canceled)7. The solid lipid particles according to claim 1 , wherein the solid lipid particles have a substantially spherical shape.8. The solid lipid particles according to claim 1 , wherein the lipid hydrophobic matrix comprises at least one of:{'sub': 6', '40, 'a mixture of monoglycerides, diglycerides, and triglycerides having a carbon number ranging from Cto C,'}{'sub': 6', '12, 'esters of fatty acids having a carbon number ranging from Cto Cwith ethylene glycol or propylene glycol;'}a mixture of triglyceridies having medium chain length; or{'sub': 18', '24, 'a mixture of glycerides having a carbon number ranging from Cto C.'}9. The solid lipid particles according to claim 1 , wherein the lipid hydrophobic matrix comprises a mixture of a wax and at least one non-neutralized fatty acid.10. A process for preparing solid lipid particles according to claim 1 , wherein the process comprises:dispersing a lipid phase having a melting point ...

Подробнее
Номер записи: 58
07-01-2016 дата публикации

TREATMENT OF PETS WITH SIRTUIN ACTIVATORS

Номер: US20160000737A1
Автор: BRUCKBAUER Antie, ZEMEL Michael
Принадлежит:

The present invention provides for systems, compositions, methods and kits for regulating energy metabolism in pets. The systems, compositions, and kits can comprise, and methods can make use of, pet foods, pet treats, pet supplements, and pet drinks. In one aspect, the invention provides for pet food, treat, supplement, and drink compositions that comprise a combination of (a) leucine, and (b) a sirtuin activator, or any precursors or metabolites of (a) or (b). These combinations may be effective for reducing weight or adipose volume in the pet. In another aspect, the invention provides for methods of regulating energy metabolism by the administration of one or more compositions comprising leucine, a leucine metabolite, and/or a sirtuin activator. The invention also provides for kits comprising compositions of leucine, a leucine metabolite, and/or a sirtuin activator packaged in an oral dose form with usage instructions. 1. A pet food composition comprising:a. about 0.05 to 5 wt % of leucine and/or about 0.005 to 1 wt % of one or more leucine metabolites; andb. about 0.0005 to 0.05 wt % of a sirtuin activator.2. A pet food , treat or supplement composition comprising:a. at least about 50 mg of leucine and/or at least about 5 mg of one or more leucine metabolites; andb. at least about 1 mg of a sirtuin activator.3. A pet food composition comprising:a. about 0.05 to 5 wt % of leucine and/or about 0.005 to 1 wt % of one or more leucine metabolites;b. about 0.0005 to 0.05 wt % of a sirtuin activator; andc. an additional component selected from the group consisting of omega-3 fatty acid, eicosapentanoic acid, choline, manganese, methionine, cysteine, L-carnitine, lysine, alpha lipoic acid, dimethylaminoethanol, pyruvic acid, actyl L-carnitine, L-carnitine, conjugated linoleic acid, diacylglyceride, chondroitin, glucosamine, ginger (or extract thereof), chicory pulp, and myrtle.4. A pet food , treat or supplement composition comprising:a. at least about 50 mg of leucine ...

Подробнее
Номер записи: 59
07-01-2016 дата публикации

A COMPOSITION FOR IMPROVING JOINT HEALTH, OR FOR PREVENTING AND TREATING RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS

Номер: US20160000844A1
Автор: BYUN Erisa, Cho Hyoung-Kwon, JEON Chang-hyun, JEONG Hyeon-ju, JUN Ki-young, KIM Dae-ki, KIM Dae-Sung, KIM Se-gun, KWON Jung-kee, KWON Young-Bae, Lee Eun-Joo, Lee Jun-kyoung, YU Jin-ju
Принадлежит:

The present invention relates to a composition for helping with joint health or preventing, alleviating or treating rheumatoid arthritis and osteoarthritis, which is based on the results of tests conducted using an inflammatory cell model, an osteoarthritis animal model and an acute arthritis animal model. 1. A composition for helping with joint health or preventing , alleviating or treating rheumatoid arthritis and osteoarthritis , which contains , as an active ingredient:an extract mixture obtained by extracting each of Kalopanacis Cortex, Chaenomelis Fructus, Angelicae Gigantis, Zingiberis Rhizoma Crudus, Raphani Semen and Saururi Herba to prepare extracts, and mixing the extracts with one another at a mixing ratio of 150-250 parts by weight of the Kalopanacis Cortex extract: 650-750 parts by weight of the Chaenomelis Fructus extract: 650-750 parts by weight of the Angelicae Gigantis extract: 50-150 parts by weight of the Zingiberis Rhizoma Crudus extract: 50-150 parts by weight of the Raphani Semen extract: 150-250 parts by weight of the Saururi Herba extract; ora dry extract mixture obtained by drying each of the extracts and mixing the dried extracts with one another at the above mixing ratio; or a mixed extract obtained by mixing Kalopanacis Cortex, Chaenomelis Fructus, Angelicae Gigantis, Zingiberis Rhizoma Crudus, Raphani Semen and Saururi Herba with one another at the above mixing ratio to prepare a mixture, and extracting the mixture.2. The composition of claim 1 , which has effects on inhibition of inflammatory cytokines and matrix metalloproteinases (MMPs) claim 1 , relief of inflammation and pain claim 1 , enhancement of activity of cartilage formation factors claim 1 , and normalization of a joint structure.3. The composition of claim 1 , wherein a number of times the extraction is performed when each of the extracts or mixed extract is prepared is two or more.45-. (canceled)6. A pharmaceutical composition for alleviating or treating rheumatoid ...

Подробнее
Номер записи: 60
07-01-2016 дата публикации

COMPOSITION FOR PREVENTING CANCER AND TREATING CANCER AND INTENSIFYING THE EFFECTS OF OTHER ANTICANCER DRUGS

Номер: US20160000856A1
Автор: Tsai Hsiu-Hsien
Принадлежит:

This invention relates to a composition derived from Chinese herbal medicines, medicinal plants and extracts thereof, and to its use for preventing cancer and treating cancer and intensifying the effects of other anticancer drugs. More specifically, the composition of the present invention is derived from various Chinese herbal medicines or medicinal plants which have a long history of human consumption. The composition of the invention is obtained through specific techniques and has revealed good cytotoxicities on Malignant Melanoma Cells, Prostate Cancer Cells and Colon Cancer Cells, Lung Cancer Cells, Stomach Cancer Cells, Breast Cancer Cells and Liver Cancer Cells. The composition of the invention has also revealed obvious intensifying the effects of other anticancer drugs. Cancer presents special problems to the medical community which the present invention address, 1. A method for preventing cancer and treating cancer and intensifying the effects of other anticancer drugs , said method is a plant aqueous extract comprises PRUNELLAE SPICA , SCUTELLARIAE BARBATAE HERBA , ANTRODIA CAMPHORATA , CURCUMAE RHIZOMA , PAEONIAE SUFFRUTICOSAE CORTEX , PATRINIAE HERBA , IXERIS HERBA and PHELLINUS LINTEUS extracts.2. The method according to wherein the weight ratio of PRUNELLAE SPICA:SCUTELLARIAE BARBATAE HERBA:ANTRODIA CAMPHORATA:CURCUMAE RHIZOMA:PAEONIAE SUFFRUTICOSAE CORTEX:PATRINIAE HERBA:IXERIS HERBA:PHELLINUS LINTEUS is about(0.5˜1.5):(0.5˜1.5):(0.5˜1.5):(0.5˜1.5):(0.5˜1.5):(0.5˜1.5):(0.5˜1.5):(0.5˜1.5).3. The method according to wherein said therapeutically effective amount is 0.4 to 120 grams per day.4. The method according to wherein the composition is administered to the subject by orally or nasally or cutaneously or parentally or anally or virginally or via eye or via ear or by spray inhalation or by implanted reservoir or operation or acupuncture.5. The method according to wherein said plant aqueous extract is in a form selected from the group consisting of ...

Подробнее
Номер записи: 61
04-01-2018 дата публикации

HOMEOPATHIC METHOD FOR TREATING COLIC, GAS AND UPSET STOMACH IN INFANTS

Номер: US20180000864A1
Автор: COURTIOL Jacqueline, LAWRENCE Timothy
Принадлежит:

The present invention generally relates to homeopathic compositions, and, more particularly, (i) homeopathic compositions comprising a homeopathically potentised form of (Passionflower), and a homeopathically potentised form of (Nutmeg); or (ii) a homeopathically potentised ; and a homeopathically potentised ; or (iii) a homeopathically potentised ; and a homeopathically potentised ; and methods of treatment using these homeopathic compositions. 142-. (canceled)43Carbo Vegetabilis. A homeopathic composition comprising homeopathically potentised formulated in a liquid suspension.44Carbo Vegetabilis. The homeopathic composition of claim 43 , wherein the homeopathically potentised form of the is at a potency of 1× or 2×.45Carbo Vegetabilis. The homeopathic composition of claim 43 , wherein the is triturated with a sugar alcohol selected from the group consisting of Xylitol claim 43 , Mannitol and Sorbitol or a combination thereof.46Carbo Vegetabilis. The homeopathic composition of claim 43 , wherein the is produced from activated carbon having an iodine number of at least 900 mg/g.47Carbo Vegetabilis. The homeopathic composition of claim 43 , wherein the comprises activated carbon particles having a mean particle size of about 15 microns to about 60 microns with at least 90% of mass contained in particles (% Подробнее

Номер записи: 62
05-01-2017 дата публикации

Compositions for Relieving the Symptoms of Gluten Sensitivity and Methods of Use Thereof

Номер: US20170000830A1
Автор: Saini Rakesh
Принадлежит:

The disclosure relates to a composition that may be used to prevent the symptoms of non-celiac gluten sensitivity and may include ingredients that degrade or inactivate gluten and other components that may cause these symptoms. 1. A composition for reducing gluten sensitivity , comprising at least three proteases;at least one carbohydrase;at least one probiotic; andwherein said composition relieves symptoms of gluten sensitivity.2. The composition of further comprising ginger and turmeric.3. The composition of wherein said composition relieves the symptoms of non-celiac gluten sensitivity.4Aspergillus oryzaeAspergillus melleus. The composition of wherein said at least three proteases are selected from the group consisting of Protease 3.0 claim 1 , Protease 4.5 claim 1 , Protease 6.0 claim 1 , Papain claim 1 , Bromelain claim 1 , Protease claim 1 , Protease claim 1 , Proteases I-V claim 1 , and DPP IV and combinations thereof.5. The composition of wherein said at least one carbohydrase is selected from the group consisting of lactase claim 1 , α-galactosidase claim 1 , β-glucanase claim 1 , xylanase claim 1 , glucoamylase claim 1 , amylase claim 1 , hemicellulase claim 1 , invertase and pectinase and combinations thereof.6Lactococcus lactisLactococcus cremoris.. The composition of wherein said at least one probiotic is selected from the group consisting of and7. The composition of wherein said composition prevents the symptoms of non-celiac gluten sensitivity where said symptoms are selected from the group consisting of abdominal pain claim 1 , cramping claim 1 , bloating/distention claim 1 , diarrhea claim 1 , constipation and fatigue and combinations thereof.8. The composition of wherein said symptoms of non-celiac gluten sensitivity are selected from the group consisting of abdominal pain claim 7 , bloating claim 7 , changes in bowel habits and fatigue and combinations thereof.9. The composition of wherein said composition reduces the concentration of gluten to ...

Подробнее
Номер записи: 63
20-01-2022 дата публикации

METHODS AND PRODUCTS FOR TREATING FOLIC ACID DEFICIENCY AND MORNING SICKNESS

Номер: US20220016120A1
Автор: Castor Trevor P
Принадлежит: Aphios Corporation

Embodiments of the present invention are directed to formulations and methods of treating folic acid deficiency and morning sickness. The dosage form has an effective amount, of a folic add with an effective amount of a gingerol composition to suppress nausea and/or gastric distress and to promote hematopoiesis. 1. A dosage form for the treatment of folic acid deficiency and morning sickness comprising an effective amount of an folic acid selected from a group comprising natural and synthetic forms of Vitamin B-9 , one of the B-complex vitamins and mixtures thereof , with an effective amount of a gingerol composition to suppress nausea and/or gastric distress , said gingerol composition selected from a group of gingerol compounds comprising 6-gingerol , 8-gingerol , 10-gingerol , 12-gingerol , 6-shogaol , 8-shogaol and 10-shogaol as single compositions and mixtures thereof.2. The dosage form of further comprising an oil base wherein the folic acid is dispersed as a solid suspension in said oil base and said gingerol composition dissolved in said oil base.3. The dosage form of wherein said oil base is held in a gel cap.4. The dosage form of wherein said gingerol composition is an extract from a ginger compound containing natural source.5. The dosage form of wherein said gingerol composition is used to wet a powder of said folic acid to form a gingerol wetted folic acid powder.6. The dosage form of wherein said gingerol wetted folic acid powder is pressed into a tablet.7. The dosage form of wherein said gingerol wetted folic acid powder is loaded into a capsule.8. The dosage form of wherein said folic acid and gingerol are dissolved or suspended in a solution.9. The dosage form of wherein said folic acid is present in 400 to 800 mcg of folic acid.10. The dosage form of wherein said gingerol composition is present in an amount effective to promote hematopoiesis.11. A method of treating morning sickness comprising the administering of a dosage form comprising an ...

Подробнее
Номер записи: 64
12-01-2017 дата публикации

Composition to Mitigate Spikes in Blood Sugar

Номер: US20170007591A1
Автор: LaChapelle Chad, Maloney Tim, Smith Matt, Stanton Jerry
Принадлежит:

Compositions comprising therapeutically effective amounts of quercetin, myricetin and chlorogenic acid are improved by the addition of one or multiple additional components, for mitigating blood sugar spikes in general and for treating diabetes specifically. Certain other additives produce additional benefits. 1. A composition comprising therapeutically effective amounts of quercetin , myricetin and chlorogenic acid in combination with curcumin.2. The composition according to claim 1 , wherein the curcumin is in an amount no greater than 12 g.3. The composition according to claim 2 , wherein the amount of curcumin is greater than 50 mg.4. The composition according to claim 1 , wherein the curcumin is in the form of an extract of turmeric root.5. The composition according to claim 1 , further comprising an agent that increases bioavailability of the curcumin in humans by at least 50%.6. The composition according to claim 5 , wherein the agent includes piperine.7. The composition according to claim 6 , wherein the piperine is in an amount greater than 20 mg.8. The composition according to claim 1 , wherein the agent is in the form of black pepper.9. The composition according to claim 1 , in combination with dried tea leaves.10. The composition according to claim 9 , wherein the composition and the dried tea leaves are combined in a flow through tea bag.11. The composition according to claim 9 , wherein content of the tea bag is characterized by no more than a trace amount of an agent that increases bioavailability of the curcumin in humans.12. A composition comprising therapeutically effective amounts of quercetin claim 9 , myricetin and chlorogenic acid in combination with capsicum.13. The composition according to claim 12 , wherein the capsicum is in an amount no greater than 8 g.14. The composition according to claim 13 , wherein the amount of capsicum is greater than 2 g.15. The composition according to claim 12 , wherein the capsicum is in the form of an extract ...

Подробнее
Номер записи: 65
14-01-2016 дата публикации

ADRENOMEDULLIN PRODUCTION ENHANCER

Номер: US20160008385A1
Автор: Kaneko Atsushi, KONO Toru, OMIYA Yuji
Принадлежит:

It is an object of the invention to discover a substance that effectively increases the production of adrenomedullin, as well as to provide an adrenomedullin production-enhancing agent utilizing this substance. The adrenomedullin production-enhancing agent is characterized by inclusion of a ginsenoside, a sanshool, and/or a shogaol as active ingredients. 2. The method according to claim 1 , wherein the compound represented by formula (1) is at least one ginsenoside selected from the group consisting of ginsenoside Rb claim 1 , ginsenoside Rb claim 1 , ginsenoside Rc claim 1 , ginsenoside Rd claim 1 , ginseonside Re claim 1 , ginsenoside Rg claim 1 , ginsenoside Rg claim 1 , and ginsenoside Rh.3. The method agent according to claim 1 , wherein the compound represented by formula (2) is at least one sanshool selected from the group consisting of α-sanshool claim 1 , β-sanshool claim 1 , γ-sanshool claim 1 , hydroxy-α-sanshool claim 1 , hydroxy-β-sanshool claim 1 , and hydroxy-γ-sanshool.4. The method according to claim 1 , wherein the compound represented by formula (3) is at least one compound selected from the group consisting of 6-shogaol claim 1 , 8-shogaol claim 1 , and 10-shogaol.6. The method according to claim 5 , wherein the crude drug comprising the compound represented by formula (1) is ginseng.7. The method according to claim 5 , wherein the crude drug comprising the compound represented by formula (2) is Japanese pepper.8. The method according to claim 5 , wherein the crude drug containing the compound represented by formula (3) is dried ginger rhizome.10. The method according to claim 9 , wherein the Kampo medicine prescription is Daikenchutou.1120-. (canceled) The present invention relates to an adrenomedullin production-enhancing agent, and more particularly to an adrenomedullin production-enhancing agent that is effective in preventing and treating diseases such as Crohn's disease by promoting the production of adrenomedullin, an intestinal peptide ...

Подробнее
Номер записи: 66
14-01-2016 дата публикации

Formulation of Curcumin with Enhanced Bioavailability of Curcumin and method of preparation and treatment thereof

Номер: US20160008479A1
Автор: Antony Benny
Принадлежит:

A medicinal composition useful for the treatment of head and neck cancer premalignant lesions. The composition includes a curcuminoid mixture and an essential oil of turmeric. The curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin. The essential oil of turmeric includes about 45% ar-turmerone. The weight ratio of curcuminoid mixture to essential oil of turmeric ranges from about 1:3 to about 99:1. Methods of preparation of the composition is provide. Methods of treatment of head and neck cancer premalignant lesions by oral administration is provided. 1. A method of treating oral premalignant lesions of head and neck , the method comprising administering a composition , the composition comprising a curcuminoid mixture and an essential oil of turmeric , the curcuminoid mixture consisting of curcumin , demethoxycurcumin and bisdemethoxycurcumin , the essential oil of turmeric comprising about 45% ar-turmerone , and a weight ratio of the curcuminoid mixture to essential oil of turmeric ranging from about 1:3 to about 99:1.2. A method of treating oral mucosal dysplasia , the method comprising administering a composition , the composition comprising a curcuminoid mixture and an essential oil of turmeric , the curcuminoid mixture consisting of curcumin , demethoxycurcumin and bisdemethoxycurcumin , the essential oil of turmeric comprising about 45% ar-turmerone , and a weight ratio of the curcuminoid mixture to essential oil of turmeric ranging from about 1:3 to about 99:1.3. A method of decreasing size of a premalignant lesion of head and neck , the method comprising administering a composition , the composition comprising a curcuminoid mixture and an essential oil of turmeric , the curcuminoid mixture consisting of curcumin , demethoxycurcumin and bisdemethoxycurcumin , the essential oil of turmeric comprising about 45% ar-turmerone , and a weight ratio of the curcuminoid mixture to essential oil of turmeric ranging from about 1:3 to ...

Подробнее
Номер записи: 67
11-01-2018 дата публикации

MODIFIED CYCLODEXTRIN COATED MAGNETITE NANOPARTICLES FOR TARGETED DELIVERY OF HYDROPHOBIC DRUGS

Номер: US20180008552A1
Автор: Joy Pattayil, Naduvilidam Jayaprabha Kunnoth
Принадлежит: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH

The invention discloses a composition comprising surface modified iron oxide nanoparticles with citric acid modified cyclodextrin with a hydrodynamic diameter of less than 10 nm and a hydrophobic molecule. 1. Beta-cyclodextrin-citrate coated magnetic nanoparticles of size 3 to 10 nm.2. A process for the preparation of Beta-cyclodextrin-citrate coated magnetic nanoparticles comprising the steps of:i. dissolving β-cyclodextrin and citric acid in a ratio ranging between 3:1 to 5:2 in water followed by stirring the mixture at a temperature in a range of 70-80° C. for period in the range of 3-4 hrs to obtain a transparent solution;ii. treating the transparent solution as obtained in step (i) with alcohol, followed by washing and drying at a temperature in the range of 60-70° C. for a period in the range of 24-26 hrs to obtain cyclodextrin-citrate complex;iii. dissolving cyclodextrin-citrate complex as obtained in step (ii) in water to obtain a cyclodextrin-citrate solution;iv. mixing ferric chloride hexahydrate and ferrous chloride tetrahydrate molar ratio ranging from 2:1 to 5:3 in water and ammonium hydroxide solution followed by stirring and washing to obtain magnetic nanoparticle;v. redispersing the magnetic nanoparticles as obtained in step (iv) followed by adding the Cyclodextrin-citrate solution as obtained in step (iii) with stirring for period in the range of 4-5 hours at temperature in the range of 80-90° C. to obtain a stable dispersion of beta-cyclodextrin coated magnetite nanoparticles;vi. dialyzing the beta-cyclodextrin coated magnetite nanoparticles dispersion obtained in step (v) against water for a period in range of 3-4 days and at a temperature in the range of 60-70° C. to obtain coated solid nanoparticles;vii. dispersing the coated nanoparticles obtained in step (vi) in water at the physiological pH to obtain Beta-cyclodextrin-citrate coated magnetite nanoparticles;3. The Beta-cyclodextrin-citrate coated magnetic nanoparticles as claimed in claim 1 , ...

Подробнее
Номер записи: 68
11-01-2018 дата публикации

USE OF TWO BOTANICALS WITH COMPLEMENTARY ACTIVITIES FOR IMPROVEMENT OF SKIN

Номер: US20180008557A1
Автор: Johnson Kent J., Varani James
Принадлежит:

A skin augmentation composition comprises a therapeutically effective amount of a combination of a gingerol and a curcumin and a cosmetically or pharmaceutically acceptable carrier. Methods for enhancing the repair of damaged skin and the prevention of developing wounds in a subject having damaged skin comprises administering to a portion of damaged skin, a composition comprising a therapeutically effective amount of a combination of a gingerol and a curcumin and a cosmetically or pharmaceutically acceptable carrier. 19.-. (canceled)10. A method for augmenting skin , the method comprising administering to the skin a composition comprising 1% to 20% (w/v) curcumin , 0.1% to 10% (w/v) 6-gingerol , and a carrier suitable for topical application wherein the carrier comprises an emollient , wherein the composition is applied to augment chronologically aged skin , diabetic skin , or photoaged skin.1117-. (canceled)18. The method of claim 10 , wherein the composition is applied to augment chronologically aged skin.19. The method of claim 10 , wherein the composition is applied to augment diabetic skin.20. The method of claim 10 , wherein the composition is applied to augment photoaged skin.2122-. (canceled)23. The method according to claim 10 , wherein the composition comprises ginger extract.24. The method according to claim 10 , wherein the composition comprises turmeric extract.25. The method according to claim 10 , wherein the composition comprises ginger extract and turmeric extract.26. The method according to claim 10 , wherein the composition comprises about 10% curcumin (w/v) and about 3% 6-gingerol (w/v).27. The method according to claim 10 , wherein the composition further comprises a member selected from the group consisting of: demethoxycurcumin claim 10 , bisdemethoxycurcumin claim 10 , (1E claim 10 ,4Z claim 10 ,6E)-5-hydroxy-1 claim 10 ,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1 claim 10 ,4 claim 10 ,6-trien-3-one claim 10 ,1 claim 10 ,7-bis(4-hydroxy-3 ...

Подробнее
Номер записи: 69
14-01-2021 дата публикации

COMPOSITION FOR RELIEVING STRESS AND ENHANCING IMMUNITY AND PREPARATION METHOD THEREOF

Номер: US20210008124A1
Автор: FANG SUYUN, HU XIAOKE, Li Yan, Liu Wei, MIN JUN, PENG JIAN, Wang Caixia, ZHANG HAIKUN
Принадлежит:

The invention belongs to the technical field of health food and particularly relates to a composition for relieving stress and enhancing immunity and a preparation method thereof. The composition for relieving stress and enhancing immunity is calculated in parts by weight, 100-300 parts of a radix curcuma extract, 100-250 parts of a sea cucumber extract, 100-250 parts of a chlorella extract, 50-150 parts of a cranberry extract, 100-300 parts of a ginseng extract, 80-150 parts of a coconut oil extract and 100-200 parts of a palm oil extract. The composition can significantly enhance the body's immunity, relieve mental stress and improve the level of human health. In addition, the composition of the present invention is suitable for long-term use and has a small adverse reaction. 1. A composition for relieving stress and enhancing immunity , characterized in , the composition for relieving stress and enhancing immunity is calculated in parts by weight , 100-300 parts of a turmeric extract , 100-250 parts of a sea cucumber extract , 100-250 parts of a chlorella extract , 50-150 parts of a cranberry extract , 100-300 parts of a ginseng extract , 80-150 parts of a coconut oil extract , and 100-200 parts of a palm oil extract.2. The composition for relieving stress and enhancing immunity according to claim 1 , characterized in claim 1 , the composition for relieving stress and enhancing immunity is calculated in parts by weight claim 1 , further comprising 50-100 parts of lecithin and 50-80 parts of 5-hydroxytryptophan.3. The composition for relieving stress and enhancing immunity according to claim 1 , characterized in claim 1 , the composition for relieving stress and enhancing immunity is calculated in parts by weight claim 1 , 150-250 parts of a turmeric extract claim 1 , 100-200 parts of a sea cucumber extract claim 1 , 150-200 parts of a chlorella extract claim 1 , 80-100 parts of a cranberry extract claim 1 , 150-250 parts of a ginseng extract claim 1 , 100-150 ...

Подробнее
Номер записи: 70
09-01-2020 дата публикации

METHOD FOR TREATING AN ALLERGIC DISEASE

Номер: US20200009110A1
Автор: LIANG Hui Ju, LIN PEI-HSIN, LO Jir-Mehng, WU Yeh B
Принадлежит: ARJIL BIOTECH HOLDING COMPANY LIMITED

The invention relates to a use of a compound for manufacturing a medicament for treating an allergic disease, wherein the compound is selected from the group consisting of ovatodiolide, 1′-acetoxychavicol acetate, zerumbone and combination thereof. Also provided is a method and a composition for treating an allergic disease. 1. A method for treating an allergic disease which comprises administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of ovatodiolide , 1′-acetoxychavicol acetate , zerumbone and combination thereof2. The method of claim 1 , wherein the compound is administered in a pharmaceutical composition.3Anisomeles indica, Alpinia galangal, Zingiber zerumbet. The method of claim 1 , wherein the compound is administered in a composition comprising an extract from an herb selected from the group consisting of and combination thereof.4. The method of claim 1 , wherein the allergic disease is selected from the group consisting of hay fever claim 1 , food allergies claim 1 , atopic dermatitis claim 1 , asthma claim 1 , psoriasis claim 1 , anaphylaxis psoriasis claim 1 , atopic dermatitis claim 1 , contact dermatitis or eczema claim 1 , autoimmune disease claim 1 , osteoarthritis claim 1 , allergy rhinitis claim 1 , seborrheic dermatitis claim 1 , psoriasis arthritis and poison ivy.5. The method of claim 4 , wherein the allergic disease is allergic dermatitis.6. The method of claim 5 , wherein the allergic dermatitis is atopic dermatitis.7. The method of claim 5 , wherein the allergic dermatitis is psoriasis.8. The method of claim 4 , wherein the allergic disease is autoimmune disease.9. The method of claim 8 , wherein the autoimmune disease is selected from the group consisting of autoimmune hepatitis claim 8 , autoimmune pancreatitis claim 8 , Sjogren' syndrome claim 8 , ulcerative colitis claim 8 , Crohn's disease claim 8 , reflex sympathetic dystrophy claim 8 , post myocardial infarction ...

Подробнее
Номер записи: 71
09-01-2020 дата публикации

CURCUMIN-CONTAINING MEDICINAL PREPARATION

Номер: US20200009211A1
Автор: Harada Kazuo, HIGASHISAKA Kazuma, NAGANO Kazuya, NAKAO Tomohiro, TSUTSUMI Yasuo
Принадлежит:

An object of the present invention is to provide a curcumin-containing solid composition to be used as a composition for treating or preventing diseases and symptoms that benefit from curcumin absorption into cells. 1. A method for treating or preventing a disease or symptom that benefits from curcumin absorption into cells , the method comprising administering a solid composition comprising:(1) curcumin;(2) hydrophilic polymer; and(3) at least one nonionic surfactant selected from the group consisting of polyglycerol fatty acid esters, sucrose fatty acid esters, and lecithins,to a subject in need thereof.2. The method according to claim 1 , wherein the disease or symptom is at least one member selected from the group consisting of:(1) diseases or symptoms that benefit from modulation of one or more transcription factors selected from the group consisting of NF-κB, AP-1, STAT, Wnt/β-catenin, Notch-1, EGR-1, CREB-BP, WT-1, HIF, ERE, Nrf-2, PPAR-α, and PPAR-γ;(2) diseases or symptoms that benefit from modulation of one or more cytokines selected from the group consisting of TNF-α, IL-2, IL-5, IL-6, IL-8, IL-12, IL-18, MCP-1, MIP-1α, and MaIP;(3) diseases or symptoms that benefit from modulation of one or more receptors selected from the group consisting of IR, ER-α, H2R, HER-2, LDLR, ITR, FasR, EPCR, AR, EGFR, IL-8R, CXCR4, AHR, and DR-5;(4) diseases or symptoms that benefit from modulation of one or more enzymes selected from the group consisting of Desaturase, GCL, AATF-1, ATFase, Telomerase, MMP, ATPase, GICL, COX-2, iNOS, NQO-1, 5-LOX, TMMP-3, DNA pol, Src-2, FPT, PhP D, GST, ODC, and ACOX-1;(5) diseases or symptoms that benefit from modulation of one or more growth factors selected from the group consisting of HGF, CTGF, FGF, NGF, PDGF, TGF-β1, EGF, VEGF, and TF;{'sup': '2+', '(6) diseases or symptoms that benefit from modulation of one or more kinases selected from the group consisting of FAK, AAPK, P60c-tk, EGFR-K, CaPK, PTK, MAPK, IL-1R AK, PKB, PKA, PAK, JAK, ...

Подробнее
Номер записи: 72
03-02-2022 дата публикации

CAPSULE-CONTAINING POUCHED PRODUCT FOR ORAL USE

Номер: US20220030928A1
Автор: Chapman Paul Stuart, Turfler David Troy
Принадлежит:

A pouched product adapted for release of a releasable component therefrom is provided herein. The pouched product can include a water-permeable fabric pouch formed so as to define a cavity therein, and a composition contained within the cavity of the water-permeable fabric pouch, the composition including one or more releasable components that are released from the composition under mouth conditions and that are capable of movement through the water-permeable fabric pouch. The composition includes nicotine and at least one particulate non-tobacco material. The pouched product also includes at least one capsule contained within the cavity of the water-permeable fabric pouch, the capsule having a capsule wall surrounding an inner payload comprising at least one botanical. 1. A pouched product adapted for oral use , comprising:a water-permeable fabric pouch formed so as to define a cavity therein;a composition contained within the cavity of the water-permeable fabric pouch, the composition comprising one or more releasable components that are released from the composition under mouth conditions and that are capable of movement through the water-permeable fabric pouch, the composition comprising nicotine and at least one particulate non-tobacco material; andat least one capsule contained within the cavity of the water-permeable fabric pouch, the at least one capsule having a capsule wall surrounding an inner payload comprising at least one botanical.2. The pouched product of claim 1 , wherein the capsule wall comprises a material configured to be broken by shear forces.3. The pouched product of claim 1 , wherein the at least one particulate non-tobacco material comprises microcrystalline cellulose.4. The pouched product of claim 1 , wherein the nicotine is synthetic nicotine.5. The pouched product of claim 4 , wherein the synthetic nicotine is in the form of S(−)-nicotine or a racemic mixture composed predominantly of S(−)-nicotine.6. The pouched product of claim 1 , ...

Подробнее
Номер записи: 73
03-02-2022 дата публикации

Kind of Chinese medicine and microcapsule preparation method suitable for nasopharyngeal carcinoma tumor inhibitor

Номер: US20220031626A1
Автор: MEI Donghai, Mei Shiqi, Ti Haowei
Принадлежит:

The invention relates to the technical field of traditional Chinese medicine, and discloses a method of traditional Chinese medicine and microcapsule preparation suitable for nasopharyngeal cancer tumor inhibitors. A traditional Chinese medicine suitable for nasopharyngeal cancer tumor inhibitors, including: Hedyotis Diffusa, Scutellaria Barbata, Arrowshaped Tinospora Root, Rehmanniae Radix Preparata, Radix Curcumae, Crotonis Fructus, Leonurus Artemisia, Ramulus Cinnamomi, Forsythiae Fructus, Taraxacum, Radix Platycodonis and White Vinegar. Among them, the raw materials for the weight ratio are as follows: 60 grams of Hedyotis Diffusa, 30 grams of Scutellaria Barbata, 9-12 grams of Arrowshaped Tinospora Root, 18 grams of Rehmanniae Radix Preparata, 19 grams of Radix Curcumae, 7.5 grams of Crotonis Fructus, 10 grams of Leonurus Artemisia, 7-10 grams of Ramulus Cinnamomi, 10 grams of Forsythiae Fructus, 15-30 grams of Taraxacum, 10 g of Radix Platycodonis, and 30 ml of White Vinegar. 1. A Chinese medicine suitable for nasopharyngeal cancer tumor inhibitors , which is characterized in that it comprises: Hedyotis Diffusa , Scutellaria Barbata , Arrowshaped Tinospora Root , Rehmanniae Radix Preparata , Radix Curcumae , Crotonis Fructus , Leonurus Artemisia , Ramulus Cinnamomi , Forsythiae Fructus , Taraxacum , Radix Platycodonis and White Vinegaris and White Vinegar. Among them , the raw materials for the weight ratio are as follows: 60 grams of Hedyotis Diffusa , 30 grams of Scutellaria Barbata , 9-12 grams of Arrowshaped Tinospora Root , 18 grams of Rehmanniae Radix Preparata , 19 grams of Radix Curcumae , 7.5 grams of Crotonis Fructus , 10 grams of Leonurus Artemisia , 7-10 grams of Ramulus Cinnamomi , 10 grams of Forsythiae Fructus , 15-30 grams of Taraxacum , 10 g of Radix Platycodonis , and 30 ml of White Vinegar.2. A preparation method of traditional Chinese medicine microcapsules suitable for nasopharyngeal cancer tumor inhibitors is characterized in that it ...

Подробнее
Номер записи: 74
03-02-2022 дата публикации

ANTI-ACHING SUPPLEMENT

Номер: US20220031763A1
Автор: AKUBUIKE NGOZICHUKWU
Принадлежит:

A composition of phyto-medicaments comprising essentially of , turmeric and for the treatment necessary to alleviate ailments associated therewith. 2. The composition of claim 1 , wherein the formulation is available as a paste or emulsion.3. The composition of claim 1 , further comprising between about 4 and 12 ounces of ginger.4. The composition of claim 1 , further comprising about 1 teaspoonful of Ceylon Cinnamon.5. The composition of claim 1 , wherein adjuvants selected from the group consisting ginger claim 1 , Ceylon Cinnamon claim 1 , honey or a combination thereof.6. The composition of claim 1 , wherein water is added to texture. People who suffer from chronic pains, nagging health issues such as stress and depression, addictions, inflammation and matters of immune health can attest to the challenges and desperation in getting or obtaining treatment for their ailments without the rigor of suffering with adverse effects of the medicaments that they have to take. It is also an issue of concern that almost all the medicament taken or consumed by these patients present yet again foreign material or abstracts into them. One can presently imagine taking opioids for pain and suffering from diarrhea as an outcome, or becoming addicted to the opioids, just as examples.In other instances, nutraceuticals and other pharmaceuticals may present medicaments that come with issues of potency and sourcing. Potency, in that nutraceuticals may come from sources that may affect the efficacy of the medicament and quality of the raw materials used. Biologics offer some solutions to sufferers and there is recognition that biologics may provide challenges because of the process and the additives that make them usable for their intended purpose or purposes.Drugs, and other non-homeopathic formulations or similarly fabricated medicines used to treat issues of anti-inflammation, agues or weight management, among others are typically tied to some adverse effects of such treatment. It ...

Подробнее
Номер записи: 75
03-02-2022 дата публикации

COMPOUND FOR TREATING OXIDATIVE STRESS IN MAMMALS

Номер: US20220031795A1
Автор: Dodds Winifred Jean
Принадлежит:

Managing and treating elevated OS biomarkers in mammals such as companion animals with at least one of the supplements alpha-lipoic acid, carnitine, co-enzyme Q-10, ginger, green tea, licorice, milk thistle, garlic, honey. resveratrol, soybeans, tomatoes, turmeric, vitamin D, vitamin E or selenium. Diagnosing an oxidative stress (OS) in a mammal comprises collecting a sample; screening the sample to detect the presence of an OS biomarker, selectively isoprostane and other antioxidants such as HODE microRNAs. TAC: GSH, MDA, and TNF-alpha. The sample can be saliva. 1. A method of using a composition to reduce an isoprostane marker indicative of oxidative stress (OS) in a dog , the composition being a combination at least vitamin D and selenium ingredients alpha-lipoic acid , co-enzyme Q-10 , green tea , and turmeric , the ingredients being mixed together in powdered form and mixed into the food and being for ingestion by the dog together with food , including the screening a saliva sample of a dog to detect a level of at least an OS isoprostane biomarker; detecting the presence of the OS isoprostane biomarker based on a quantitative level of the OS isoprostane biomarker , diagnosing the degree of OS in the dog based on an increased quantitative level of the OS isoprostane biomarker , and treating a dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker with the combination composition to lower the level below 1.75 ng/ml wherein the isoprostane biomarker in the dog so treated by the composition combination is reduced.2. The method for treating oxidative stress (OS) as claimed in including treating an elevated HODE OS biomarker in the dog.3. The method for treating oxidative stress (OS) as claimed in including in the combination at least two supplements selected from the group consisting of ginger claim 2 , licorice and garlic.4. The method for treating oxidative stress (OS) as claimed in including in the combination ginger claim 2 , licorice and ...

Подробнее
Номер записи: 76
15-01-2015 дата публикации

METHODS AND PRODUCTS TO PROVIDE ORAL NUTRITIONAL CARE TO SUBJECTS WITH DEMENTIA

Номер: US20150017147A1
Автор: Gillespie John
Принадлежит: D&E Gillespie Enterprises LLC

The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm. Such food products, when administered to affected subjects, can positively impact (i) nutritional status; (ii) quality of life; (iii) disease course; (v) the demand for assistance from a care giver; (vi) subject compliance with a nutritional plan using the food product, and (vii) ease of monitoring compliance by the caregiver for verification. 1. A product comprising a reversibly closed container and a soup , wherein the soup is in the container and comprises:a. a total volume of 200 to 2000 ml;b. at least one of a vegetable component and a meat component;c. 300 to 2500 calories; i. 20% to 80% fat;', 'ii. 10% to 45% protein; and', 'iii. 10% to 65% carbohydrate; and', 'iv. about 2% to about 40% medium chain triglycerides,, 'd. a macronutrient caloric distribution comprisinge. optionally one or more antioxidants in a total amount of at least 100 mg equivalents of vitamin C by FRSA;f. optionally omega 3 fatty acids in an amount of at least 100 mg; andg. optionally a means for extending the stability of the product.2. The product of comprising omega 3 fatty acids in an amount of 100 to 2000 mg claim 1 , and comprising antioxidants in a total amount of 100 mg to 500 mg equivalents of vitamin C by FRSA.3. The product of wherein the product claim 1 , when provided daily to a subject with ...

Подробнее
Номер записи: 77
15-01-2015 дата публикации

METHOD FOR PRODUCING A TISSUE PAPER SHEET MATERIAL CONTAINING AN ADJUVANT SUBSTANCE FOR THE TREATMENT OF ALLERGIC RHINITIS, AND THE PRODUCT OBTAINED

Номер: US20150017224A1
Автор: STEFANI Emi
Принадлежит:

The following steps are provided for producing a sheet cellulose material, for instance a handkerchief, comprising at least one adjuvant substance for the treatment of allergic rhinitis: 1. A method for producing a cellulose sheet material having a cellulose fiber-based structure and comprising at least one adjuvant substance for the treatment of allergic rhinitis , said method comprising the steps of:forming a mixture of the at least one adjuvant substance for the treatment of allergic rhinitis with at least one non-ionic surface-active agent;mixing the mixture of non-ionic surface-active agent and the at least one adjuvant substance for the treatment of allergic rhinitis in an aqueous solution of a cationic surface-active agent forming an aqueous nano- or micro-emulsion containing nano- or micro-droplet of the at least one substance encapsulated in a protective layer comprising a non-ionic surface-active agent;applying said nano- or micro-emulsion to the cellulose material;evaporating water, leading to the formation of nano- or micro-capsules anchored to the cellulose fibers.2. Method according to claim 1 , wherein said at least one adjuvant substance for the treatment of allergic rhinitis is a substance of plant origin claim 1 , preferably an essential oil.3. Method according to claim 1 , wherein said at least one adjuvant substance for the treatment of allergic rhinitis comprises at least two essential oils claim 1 , at least one of which is an adjuvant for the treatment of allergic rhinitis.4Cardiospermum HalicacabumEchium PlantagineumMelaleuca AlternifoliaEugenia CaryophyllataCupressus SempervirensOriganum MajoranaPinus SylvestrisHelianthus AnnuusHyssopus officinalisArtemisia. Method according to claim 1 , wherein the adjuvant substance for the treatment of allergic rhinitis contains at least one and preferably two essential oils selected from the group comprising: essential oil claim 1 , seed extract claim 1 , essential oil claim 1 , Ginger essential oil ...

Подробнее
Номер записи: 78
21-01-2016 дата публикации

NOVEL AND SYNERGISTIC COMPOSITION OF LECITHIN AND LYSOLECITHIN FOR IMPROVING BIOAVAILABILITY AND SOLUBILITY OF HYDROPHOBIC COMPOUNDS AND EXTRACTS

Номер: US20160015813A1
Автор: BHUPATHIRAJU Kiran, GOKARAJU Ganga Raju, GOKARAJU Rama Raju, GOLAKOTI Trimurtulu
Принадлежит:

The present invention discloses a composition(s) of hydrophobic plant molecule(s) and/or extract(s) with enhanced bioavailability comprising hydrophobic active and synergetic combination of lecithin and lysolecithin and to the process for preparation thereof. 1. A composition for use in a therapeutic formulation , comprising;a synergistic mixture comprising from about 5% to about 25% of lecithin; and from about 75% to about 95% of lysolecithin, based on the combined weight of said lecithin and said lysolecithin; in combination with:a hydrophobic active ingredient.2. The composition of claim 1 , comprising:said synergistic mixture in an amount of from about 50% to about 99.99% by weight; andsaid hydrophobic active ingredient in an amount of from about 0.01 to 50% by weight; based on the combined weight of said synergistic mixture and said active ingredient.3. The composition of claim 3 , wherein:the active ingredient is at least one compound selected from the group consisting of a curcuminoid, a boswellic acid, resveratrol, hypericin, a bacoside, xanthorhizol, luteolin, Coenzyme Q10, pyrogallol, genistein, wogonin, morin, kaempferol, salts thereof, and derivatives thereof.4. The dosage form of claim 2 , wherein the active ingredient is a natural compound claim 2 , a semi-synthetic compound claim 2 , or a synthetic compound.5. A composition for use in a therapeutic formulation claim 2 , comprising;a synergistic mixture comprising from about 5% to about 25% of lecithin; and from about 75% to about 95% of lysolecithin, based on the combined weight of said lecithin and said lysolecithin; in combination with:a hydrophobic active ingredient, wherein the active ingredient is berberine, a salt thereof, or a derivative thereof.6. A composition of claim 1 , comprising;said synergistic mixture comprising from about 5% to about 25% of lecithin; and from about 75% to about 95% of lysolecithin, based on the combined weight of said lecithin and said lysolecithin; in combination ...

Подробнее
Номер записи: 79
16-01-2020 дата публикации

COMPOSITIONS AND METHODS FOR PREVENTING AND RECOVERY FROM DETRIMENTAL EFFECTS OF ALCOHOL CONSUMPTION

Номер: US20200016117A1
Автор: Powell Brooks Alexander Reid
Принадлежит:

Disclosed are compositions, devices, and methods to prevent and recover from detrimental effects of alcohol consumption, including significant undesirable symptoms of a hangover consciously felt by the alcohol consumer, as well as those that may not be consciously experienced. The present technology comprehensively targets multiple negative effects of hangovers. In one aspect, a composition includes dihydromyricetin (DHM); and N-acetyl cysteine (NAC). The composition may further include Prickly Pear Extract, Milk Thistle, Ginger Root, Vitamins B, C, and E, electrolytes, and/or sugars. 1. A composition for mitigating adverse effects of alcohol consumption by a person , comprising:dihydromyricetin (DHM);N-acetyl cysteine (NAC);prickly pear extract; andsilymarin.2. The composition of claim 1 ,wherein the composition includes between 50 wt. % to 65 wt. % of the DHM, between 15 wt. % to 25 wt. % of the NAC, between 5 wt. % to 15 wt. % of the prickly pear extract, and between 10 wt. % to 20 wt. % of the silymarin.3. The composition of claim 1 ,wherein the DHM includes an amount of at least 300 mg, the NAC includes an amount of at least 100 mg, the prickly pear extract includes an amount of at least 50 mg, and the silymarin includes an amount of at least 100 mg.4. The composition of claim 1 , further comprising one or more B vitamins selected from a group consisting of thiamine claim 1 , riboflavin claim 1 , niacin claim 1 , pantothenic acid claim 1 , pyridoxine claim 1 , pyridoxal claim 1 , biotin claim 1 , folic acid claim 1 , and cobalamin.5. The composition of claim 4 ,wherein the composition includes between 35 wt. % to 55 wt. % of the DHM, between 10 wt. % to 20 wt. % of the NAC, between 1 wt. % to 15 wt. % of the prickly pear extract, between 5 wt. % to 20 wt. % of the silymarin, and 5 wt. % to 20 wt. % of the one or more B vitamins, orwherein the DHM includes an amount of at least 300 mg, the NAC includes an amount of at least 100 mg, the prickly pear extract ...

Подробнее
Номер записи: 80
21-01-2021 дата публикации

A NOVEL SYNERGIC HERBAL FORMULATION FOR THE PREVENTION AND TREATMENT OF PRE-DIABETES, DIABETES AND OTHER INSULIN RESISTANCE CASES

Номер: US20210015883A1
Автор: Hingorani Lal
Принадлежит:

The present invention relates to a novel synergic herbal formulation comprising Curcuma longa and Phylanthus emblica in precise combination along with one or more other ingredient for prevention and treatment of pre-diabetes, diabetes mellitus and other insulin resistance cases. Further the present invention provides a process for preparing the novel synergistic herbal formulation. 1. A novel synergistic herbal formulation comprising;a. 20% to 30% by w/w of Curcuma longa alcohol extract,b. 5% to 10% by w/w of Curcuma longa water extract,c. 1% to 10% by w/w of Turmerone oil,d. 20% to 50% by w/w of Phylanthus emblica juice powder,e. 20% to 50% by w/w of Phylanthus emblica extract,f. 10% to 15% by w/w of Phosphatidyl choline2. The novel synergistic herbal formulation as claimed in wherein Curcuma longa alcohol extract and water extract used in said formulation is extracted from Curcuma Longa Rhizomes and is 90% to 95% Curcuminoids.3. The novel synergistic herbal formulation as claimed in claim 1 , wherein the Curcuma longa water extract contains 30% to 50% of polysaccharides and turmerone oil contains 50% to 70% α-turmerone.4. The novel synergistic herbal formulation as claimed in claim 1 , wherein Phylanthus emblica juice powder contains 0.2 to 2% Vitamin C and 4 to 5.5% Gallic acid.5. The novel synergistic herbal formulation as claimed in claim 1 , wherein Phylanthus emblica extract contains 30 to 45% of tannins and 10 to 12% Gallic acid.6. The novel synergistic herbal formulation as claimed in claim 1 , wherein Phosphatidyl choline used in said formulation is 40% to 90% non GMO soya lecithin or sunflower lecithin.7. The novel synergistic herbal formulation as claimed in claim 1 , wherein the formulation contains chromium-1 ppm to 3 ppm which is an insulin sensitizer.8. The novel synergistic herbal formulation as claimed in claim 1 , wherein the formulation processed as a powder to formulate into capsule claim 1 , tablet claim 1 , granules claim 1 , sachets or liquid ...

Подробнее
Номер записи: 81
16-01-2020 дата публикации

ORALLY ADMINISTERED COMPOSITION FOR TREATING CYSTIC FIBROSIS, COPD, ASTHMA AND OTHER INFLAMMATORY CONDITIONS

Номер: US20200016228A1
Автор: Burch Lauranell H.
Принадлежит:

The invention relates to a new orally administered composition, which in present embodiments is a standardized phytochemical formulation but other embodiments may contain designed molecules. This formulation is capable of suppressing inflammation in a variety of disease conditions having an underlying inflammatory component, including but not limited to cystic fibrosis, COPD, asthma, and pancreatitis. It is an objective of the invention to provide a non-toxic therapy, which exhibits anti-oxidant anti-inflammatory properties without deleterious side effects. 1. A composition for oral administration that is suitable for the treatment of an inflammatory condition in animals or humans , consisting of combinations of five or more natural and/or synthetic molecules that have anti-inflammatory and/or CFTR modulating functions wherein one or more compounds within the composition is capable of the following functions:(1) Molecule(s) demonstrated to reduce inflammation in experimental models and/or in vivo.(2) Molecule(s) demonstrated in experimental systems and/or in vivo to act as corrector(s) of CFTR.(3) Molecule(s) demonstrated in experimental systems and/or in vivo to act as potentiator(s) of CFTR.(4) Molecule(s) demonstrated in experimental systems and/or in vivo to increase levels of cyclic AMP.(5) Molecule(s) demonstrated in experimental systems and/or in vivo to act as phosphodiesterase inhibitors.2. A composition according to claim 1 , wherein the compounds are selected from the classes of molecules consisting of: proanthocyanidins claim 1 , anthocyanins claim 1 , procyanidins claim 1 , catechins claim 1 , flavones claim 1 , flavone glycosides claim 1 , flavonoids claim 1 , isoflavones claim 1 , curcuminoids claim 1 , lipoic acids claim 1 , stilbenes and stilbenoids claim 1 , terpenes and terpenoids claim 1 , diterpenes claim 1 , triterpenes claim 1 , pentacyclic tri-terpenes claim 1 , carotenoids claim 1 , rutosides claim 1 , bithiazoles claim 1 , ...

Подробнее
Номер записи: 82
28-01-2016 дата публикации

Method for preparing pharmaceutical compositions of rhizomes from alpinia galanga or alpinia conchigera having a high content of 1's-1'-acetoxychavicol acetate (aca)

Номер: US20160022756A1
Автор: Henrik Byrial JAKOBSEN, Ina GIVERSEN
Принадлежит: NERTHUS APS

The present invention relates to a method for preparing a granulate composition of rhizomes from Alpinia galanga or Alpinia conchigera having a high and stable content of 1′S-1′-acetoxychavicol acetate and low microbiological count, which is suitable for preparing orally ingestible dosage forms such as tablets or capsules.

Подробнее
Номер записи: 83
28-01-2016 дата публикации

NANOPARTICLES FOR MITOCHONDRIAL TRAFFICKING OF AGENTS

Номер: US20160022825A1
Автор: Dhar Shanta, Marrache Sean M.
Принадлежит: University of Georgia Research Foundation, Inc.

Nanoparticles include a core, a hydrophilic layer around the core, and one or more mitochondrial targeting moieties, and may optionally include one or more contrast agents or one or more therapeutic agents. For effective mitochondrial targeting the nanoparticles have a diameter of about 200 nm or less or have a zeta potential of about 0 mV or more. 1. A nanoparticle , comprising:a hydrophobic nanoparticle core;a hydrophilic layer surrounding the core; anda mitochondrial targeting moiety,wherein the nanoparticle has a diameter of about 200 nanometers or less and has a zeta potential of about 0 mV or greater.2. A nanoparticle according to claim 1 , wherein the nanoparticle has a diameter of from about 10 nanometers to about 250 nanometers.3. A nanoparticle according to claim 1 , wherein the nanoparticle has a diameter of from about 80 nanometers to about 100 nanometers.4. A nanoparticle according to claim 1 , wherein the nanoparticle has a zeta potential of about 1 mV or greater.5. A nanoparticle according to claim 1 , wherein the nanoparticle has a zeta potential of about 7 mV or greater.6. A nanoparticle according to claim 1 , wherein the nanoparticle has a zeta potential of about 20 mV or greater.7. A nanoparticle according to claim 1 , wherein the nanoparticle has a zeta potential of about 25 mV or greater.8. A nanoparticle according to claim 1 , wherein the mitochondrial targeting moiety comprises a moiety selected from the group consisting of a triphenyl phosophonium (TPP) moiety claim 1 , a Szeto-Shiller peptide claim 1 , and a rhodamine cation.9. A nanoparticle according to claim 1 , wherein the mitochondrial targeting moiety comprises a triphenyl phosophonium (TPP) moiety or a derivative thereof.10. A nanoparticle according to claim 1 , wherein the mitochondrial targeting moiety is attached to the core via a hydrophilic polymer moiety.11. A nanoparticle according to claim 10 , wherein the hydrophilic polymer moiety comprises PEG.12. A nanoparticle according ...

Подробнее
Номер записи: 84
26-01-2017 дата публикации

COMPOSITIONS AND METHODS FOR COMBINATION INGREDIENT DELIVERY

Номер: US20170020811A1
Автор: Allio Michael K., Lane Stephen, Wo Marco
Принадлежит:

Described herein are compositions, methods, and devices for relief of a cough, cold, sore throat, or allergy, or a related symptom. Also described herein are compositions, methods, and devices for the prevention, treatment and/or amelioration of a digestive illness or digestive discomfort, or a related symptom of either. 1. A composition comprising:a plurality of active pharmaceutical ingredients, wherein the plurality of pharmaceutical ingredients comprises an analgesic, anesthetic, antihistamine, antitussive, expectorant, decongestant, or demulcent, and wherein each of the active pharmaceutical ingredients provides relief for a cold, cough, or a sore throat, or a related symptom; anda plurality of botanical ingredients,wherein the plurality of active pharmaceutical ingredients and the plurality of botanical ingredients are present in a ratio by weight of about 1:32 to 1:65.2. The composition of claim 1 , wherein the plurality of active pharmaceutical ingredients and the plurality of botanical ingredients are present in a ratio by weight of about 1:64.310-. (canceled)11. The composition of claim 1 , wherein the analgesic claim 1 , anesthetic claim 1 , antihistamine claim 1 , antitussive claim 1 , expectorant claim 1 , decongestant claim 1 , or demulcent comprises acetaminophen claim 1 , ibuprofen claim 1 , ketoprofen claim 1 , aspirin claim 1 , naproxen claim 1 , benzocaine claim 1 , lidocaine claim 1 , dyclonine claim 1 , hexylresorcinol claim 1 , brompheniramine claim 1 , chlorpheniramine claim 1 , diphenhydramine claim 1 , dimenhydrinate guaifenesin claim 1 , phenylephrine claim 1 , pseudoephedrine claim 1 , glycerin claim 1 , or menthol.12. The composition of claim 1 , wherein the plurality of active pharmaceutical ingredients comprises at least three of: aspirin claim 1 , naproxen claim 1 , ibuprofen claim 1 , acetaminophen claim 1 , menthol claim 1 , benzocaine claim 1 , lidocaine claim 1 , dyclonine claim 1 , hexylresorcinol claim 1 , or ketoprofen.13. The ...

Подробнее
Номер записи: 85
26-01-2017 дата публикации

ANALGESIC COMPOSITIONS AND METHODS OF USE

Номер: US20170020946A1
Автор: Cozart William T.
Принадлежит:

The invention relates to the fields of pharmacology and medicine, and provides anesthetic compositions and methods for the treatment of pain using compositions comprising Tea tree oil and one or more additional agent. The invention relates to analgesic compositions for the treatment of pain associated with a variety of disorders or conditions, particularly oral or dental disorders or conditions such as alveolar osteitis or dental caries. 1. An anesthetic composition comprising a combination of Tea tree oil and one or more additional agent , comprising 0.1 ml to 1.0 ml of Tea tree oil.2. The anesthetic composition of claim 1 , wherein the ratio of Tea tree oil to the one or more additional agent is a 6:1 part by weight relationship.3. The composition of claim 1 , wherein the additional agent is selected from the group consisting of Ginger root oil claim 1 , Peppermint leaf oil claim 1 , Chamomile flower oil claim 1 , Olive leaf extract oil claim 1 , Grape seed oil claim 1 , Clove oil claim 1 , a flavoring syrup claim 1 , and an additional anesthetic agent.4. The composition of claim 3 , wherein the flavoring syrup is Cherry syrup.5. The composition of claim 3 , wherein the additional anesthetic agent is a topical anesthetic agent.6. The composition of claim 5 , wherein the topical anesthetic agent is selected from the group consisting of benzocaine claim 5 , lidocaine claim 5 , and tetracaine.7. The composition of claim 5 , wherein the topical anesthetic is benzocaine.8. The composition of claim 2 , comprising the Tea tree oil claim 2 , Ginger root oil claim 2 , Peppermint leaf oil claim 2 , Chamomile flower oil claim 2 , Olive leaf extract oil claim 2 , Grape seed oil claim 2 , Clove oil claim 2 , the flavoring syrup claim 2 , and an additional anesthetic agent in a ratio of about a 6:1:1:1:1:1:1:1:1 part by weight relationship.9. The composition of claim 1 , wherein the composition further comprises zinc oxide and/or water soluble poly(ethyleneglycol) (PEG).10. The ...

Подробнее
Номер записи: 86
26-01-2017 дата публикации

PHYTOCOMPLEXES EXHIBITING MULTIPLE, SYNERGISTIC ANTIOXIDANT ACTIVITIES USEFUL IN FOODS, DIETARY SUPPLEMENTS, COSMETICS AND PHARMACEUTICAL PREPARATIONS

Номер: US20170020948A1
Автор: Babish John G., DAHLBERG Clinton J., Gao Wei, Kaadige Mohan, Khang Zhe, Kou Xiaolan, Krig Sheryl, Ou Joseph, Tripp Matthew L.
Принадлежит: Nature's Sunshine Products, Inc.

Compositions comprising apple, grape, green tea, and olive extracts are presented herein. This synergistic formulations apple, grape, green tea, and olive extract are in amounts that provide a greater antioxidant activity or protein kinase modulating activity than provided by an equivalent amount of any one extract or a sum of the extracts. Further presented are methods of regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent. Also presented are methods of making an activity enhancing composition for regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent. 1. An oxidative stress modulating composition comprising:a combination of apple, grape, green tea, and olive extract in amounts that provide a greater antioxidant activity than provided by an equivalent amount of any one extract or a sum of the extracts.2Malus pumila.. The composition of claim 1 , wherein the apple extract comprises an extract of a species3Vitis vinifera.. The composition of claim 1 , wherein the grape extract comprises an extract of a species4Camellia sinensis.. The composition of claim 1 , wherein the green tea extract comprises an extract of leaves of a species5Olea europea europaea.. The composition of claim 1 , wherein the olive extract comprises an extract of a subspecies6. The composition of claim 1 , wherein at least one of the extracts in the composition is present in a different amount than an amount of at least one of another extract.7. The composition of claim 1 , wherein the apple claim 1 , grape claim 1 , green tea claim 1 , and olive extracts are present in the composition at a weight ratio of about 1:1:1:1.8. The composition of claim 1 , wherein the apple claim 1 , grape claim 1 , green tea claim 1 , and olive extracts are present in the composition at a weight ratio of about 6:1:3:19. The composition of claim 1 ...

Подробнее
Номер записи: 87
17-04-2014 дата публикации

MERRIMIA TRIDENTATA COMPOSITIONS

Номер: US20140105962A1
Автор: Patel Vimal
Принадлежит:

A composition including a powder or extract of Merremia Tridentata mixed with a liposome carrier. The liposome carrier may be a lotion, cream or suspension. The composition may be used to treat Osteophytes of the spine, feet, hands, and knees. 1. A composition comprising Merremia Tridentata , the composition further comprising a topical carrier for an application to a surface of an animal body , wherein the carrier comprises a liposome.2. The composition of claim 1 , wherein the Merremia Tridentata is in the form of at least one of an extract and a powder.3. The composition of claim 2 , wherein the extract is an oil extract.4. The composition of claim 3 , wherein the oil extract is Prasarini oil.5. The composition of claim 4 , wherein the Prasarini oil is at a concentration in the carrier of at least about 1.25 g/ml to up to about 6.35 g/ml.6. The composition of claim 4 , wherein the Prasarini oil is further mixed with Mahanarayana oil.7. The composition of claim 6 , wherein the Parasarini oil and the Maharayana oil are at a ratio of at least about 3:1 and up to about 1:3.8. The composition of claim 4 , wherein 100 ml of the Prasarini oil comprises: Prasarini 7.778 g; Sahachara 7.778 g; Sathavari 7.78 g; Bala 7.78 g; Atmagupta 7.78 g; Asvagandha 7.78 g; Ketaki 7.78 g; Tagara 0.039g; Madana 0.039 g; Kushtha 0.039 g; Kesara 0.039 g; Mustaka 0.039 g; Tvak 0.039 g; Rasna 0.039 g; Saindhva 0.039 g; Pippalavu 0.039 g; Mamsi 0.039 g; Manjistha 0.039 g; Meda 0.039 g; Mahameda 0.039 g; Jivaka 0.039 g; Rsabha 0.039 g; Satapusha 0.039 g; Vyaghranakha 0.039 g; Sunti 0.039 g; Devahva 0.039 g; Kakoli 0.039 g; Ksirakakoli 0.039 g; Vaca 0.039 g; Bhallataka 0.039 g; Paya 10 ml; Masu 10 ml; Sukta 10 ml; and Mamsasarasa 10 ml.9. The composition of claim 1 , further comprising Turmeric.10. The composition of claim 1 , further comprising clove oil claim 1 , wintergreen oil claim 1 , and Boswelia oil.11. The composition of claim 1 , wherein the topical carrier is in the form of a cream ...

Подробнее
Номер записи: 88
25-01-2018 дата публикации

USES OF HYDROXYBENZOPHENONE IN PREPARATION OF ANTIVIRAL AND ANTITUMOR DRUGS

Номер: US20180021269A1
Автор: JIANG GUANGYU, QIN WEIHUA
Принадлежит:

The present invention relates to uses of a benzophenone compound and analogues thereof having a symmetrical core structure and having same or different number of hydroxyl substitutions in benzene rings in the preparation of drugs for preventing and treating viral infections and anti-tumor drugs, in particular the use in the preparation of drugs for preventing and treating HIV, herpes virus and papillomavirus infection and the diseases induced thereby, wherein such viral infections include AIDS, genital warts, flat warts, common warts, herpes simplex, herpes zoster, vaginitis, cervicitis, cervical erosion and senile dementia, as well as cervical cancer, lung cancer, gastric cancer and colon cancer induced thereby, by means of preparing the hydroxy-substituted benzophenones and analogues thereof together with various compatible excipients into different medicaments or personal disinfected sanitary articles. 1. Use of a hydroxy-substituted benzophenone compound in the preparation of drugs for prevention and treatment of viral infections and anti-tumor drugs , wherein the hydroxy-substituted benzophenone compound is a compound selected from the group consisting of 2 ,3 ,4 ,2′ ,3′ ,4′-hexahydroxybenzophenone , 2 ,3 ,4 ,2′ ,4′ ,5-hexahydroxybenzophenone and 3 ,4 ,5 ,2′ ,3′ ,4′ ,-hexahydroxybenzophenone.2. The use according to claim 1 , wherein an effective amount of the compound and/or a composition containing the compound as an active ingredient are prepared together with various excipients for injections or oral preparations into power injections claim 1 , water injections claim 1 , infusions claim 1 , tablets claim 1 , capsules claim 1 , granules or solutions.3. The use according to claim 1 , an effective amount of the compound and/or a composition containing the compound as an active ingredient are prepared together with various compatible excipients for mucocutaneous preparations into pastes claim 1 , gels claim 1 , suppositories claim 1 , tablets claim 1 , lotions ...

Подробнее
Номер записи: 89
10-02-2022 дата публикации

ULTRAPURE PHENOL COMPOSITIONS

Номер: US20220040141A1
Автор: COLE Bradley J., DENENBERG Steven L., TANEV Nikola N.
Принадлежит: Blue Harvest, LLC

A composition can include a cannabinoid and caprylic acid triglyceride. 1. A composition comprising:60 wt % to 99.99 wt % caprylic acid triglyceride.2. The composition of claim 1 , wherein composition includes 90 wt % to 99.99 wt % caprylic acid triglyceride.3. The composition of claim 1 , wherein composition includes 0.01 wt % to 40 wt % cannabidiol.4. The composition of claim 3 , wherein the cannabidiol is of at least 95% purity.5. The composition of claim 3 , wherein the cannabidiol is of at least 97% purity.6. The composition of claim 3 , wherein the cannabidiol is of at least 98% purity.7. The composition of claim 3 , wherein the cannabidiol is of at least 99% purity.8. The composition of claim 1 , further comprising a terpene claim 1 , flavonoid claim 1 , polyphenolic claim 1 , tumeric claim 1 , ginger claim 1 , lavender claim 1 , cumin claim 1 , valerian root claim 1 , chamomile claim 1 , arnica claim 1 , humulene claim 1 , white willow bark claim 1 , or cinnamon.9. A composition consisting essentially of a cannabinoid claim 1 , caprylic acid triglyceride and claim 1 , optionally claim 1 , 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 or 5 different plant based additives.10. The composition of claim 9 , wherein the weight ratio of cannabinoid to caprylic acid triglyceride is between 1:500 and 1:10.11. The composition of claim 9 , wherein the weight ratio of cannabinoid to caprylic acid triglyceride is between 1:250 and 1:20.12. The composition of claim 9 , wherein the composition has up to 5wt % of the plant based additive.13. The composition of claim 9 , wherein the plant based additive is a terpene claim 9 , flavonoid claim 9 , polyphenolic claim 9 , tumeric claim 9 , ginger claim 9 , lavender claim 9 , cumin claim 9 , valerian root claim 9 , chamomile claim 9 , arnica claim 9 , humulene claim 9 , white willow bark claim 9 , or cinnamon.14. The composition of claim 9 , wherein the cannabinoid includes one or more of cannabinol claim 9 , cannabidiol claim 9 , ...

Подробнее
Номер записи: 90
10-02-2022 дата публикации

Compositions and methods for nutritional supplements

Номер: US20220040251A1
Автор: Hartley Pond
Принадлежит: DailyColors Health Inc

Compositions and methods are presented in which a plurality of chemically distinct polyphenols inhibit multiple enzymes in pathways associated with health and healthy ageing. Preferred compositions are derived from colored plant materials that are commonly found in the Mediterranean diet and provide the biochemical basis for the health benefits of the Mediterranean diet. Notably, the enzyme inhibition observed with the combined polyphenols was synergistic with respect to not one but a significant number of enzymes in the pathways associated with health and healthy ageing, thus providing an amplified desirable effect.

Подробнее
Номер записи: 91
22-01-2015 дата публикации

PHYTOCOMPOSITION FOR THE TREATMENT OF PAIN RELATED TO JOINT DISEASES

Номер: US20150024075A1
Автор: Velez-Rivera Héctor de Jesús
Принадлежит:

It is disclosed a phytocomposition which includes: (a) 0.01 wt % to 26 wt % of extract; (b) 0.01 wt % to 26 wt % of extract; (c) 0.01 wt % to 26 wt % of extract; and (d) 0.01 wt % to 26 wt % of extract. Said phytocomposition can be used in combination with a pharmaceutically acceptable carrier in order to obtain a pharmaceutical composition that can be used for treating muscle, arthritic and rheumatic pain in a patient, caused by joint diseases, in particular rheumatoid arthritis, osteoarthritis, fibromyalgia, gouty arthritis, psoriatic arthritis, lupus and juvenile arthritis. 1. A phytocomposition comprising the following weight percentage concentrations of the total weight of the phytocomposition:{'i': 'Arnica montana;', 'a) from 0.01% to 15% of an extract of'}{'i': 'Rosmarinus officinalis;', 'b) from 0.01% to 15% of an extract of'}{'i': 'Zingiber officinale', 'c) from 0.01% to 15% of an extract of ; and'}{'i': 'Boswellia serrata.', 'd) from 0.01% to 15% of an extract of'}23.-. (canceled)4. A phytocomposition according to claim 1 , wherein the extracts are present in the phytocomposition according to the following weight percentage concentrations of the total weight of the phytocomposition{'i': 'Arnica montana;', 'a) from 8% to 12% of the extract of'}{'i': 'Rosmarinus officinalis;', 'b) from 8% to 12% of the extract of'}{'i': 'Zingiber officinale', 'c) from 8% to 12% of the extract of ; and,'}{'i': 'Boswellia serrata.', 'd) from 8% to 12% of the extract of'}5Arnica montana, Rosmarinus officinalis, Zingiber officinaleBoswellia serrata. A phytocomposition according to claim 1 , wherein the extracts of and claim 1 , are selected from the group consisting of aqueous extracts claim 1 , alcoholic extracts and hydro-alcoholic extracts.6. A phytocomposition according to claim 5 , wherein the selected extracts selected are hydro-alcoholic extracts.7. A pharmaceutical composition claim 1 , wherein it comprises a therapeutically effective amount of the phytocomposition as ...

Подробнее
Номер записи: 92
22-01-2015 дата публикации

STEROL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF

Номер: US20150025130A1
Автор: Duan Zhenwen, Guo Shuren, Li Xuemei
Принадлежит:

The present disclosure discloses a sterol derivative, a preparation method therefor and a use thereof. The sterol derivative includes a sterol compound with Structural Formula (I) or a pharmaceutically acceptable salt thereof, or an extract containing the sterol compound, or a composition containing the sterol compound, wherein Structural Formula (I) is as follows: 3. The sterol compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein in the sterol compound with Structural Formula (I) claim 1 , R═R═R═R═—OC(═O)—CH claim 1 , or R═R═R═R=—OTs.4. A preparation method for the sterol compound according to claim 1 , wherein the preparation method comprises the following steps:{'i': 'Monascus', 'taking a -fermented rice preparation, performing ultrasonic extraction after adding a solvent, and concentrating an extract liquid under reduced pressure to obtain a refined extract;'}performing column chromatography separation for the refined extract on silica gel, performing gradient elution for the refined extract by using petroleum ether and ethyl acetate during the separation process; volume ratios of petroleum ether to ethyl acetate during the gradient elution process are 75:25, 50:50 to 25:75 and 0:100 in turn;using a mixed solution of dichloromethane and methanol with a volume ratio of 1:1 as the mobile phase, performing sephadex LH-20 gel column chromatography for an eluent obtained when the volume ratio of petroleum ether to ethyl acetate is 50:50 to 25:75, combining identical parts through Thin Layer Chromatography (TLC) tracking and detection to obtain 6 parts of fractions;performing column chromatography separation for the fourth part of fractions, wherein the chromatographic column is a C18 reversed-phase silica gel column and the mobile phase is a mixed solution of methanol and water with a volume ratio of 75:25; through TLC detection, removing an impurity band and then collecting the sterol compound.5. The preparation method according to ...

Подробнее
Номер записи: 93
02-02-2017 дата публикации

DRUG COMPOSITION AND METHOD FOR PREPARING THE SAME

Номер: US20170027877A1
Автор: Huang Wei-Ting, Lee Yi-Chi, LIU DEAN-MO
Принадлежит: NATIONAL CHIAO TUNG UNIVERSITY

The present invention provides a method for preparing a drug composition, which includes steps of dispersing an amphiphilic chitosan derivative, at least a hydrophobic drug, and at least a hydrophilic drug into a solvent to form a mixture solution, and the pH value of the mixture solution is adjusted to a range without precipitating the hydrophilic drug(s) and the hydrophobic drug(s), wherein the amphiphilic chitosan derivative is modified by a plurality of hydrophilic group(s) and a plurality of hydrophobic group(s); and after stirring the mixture solution for at least 12 hours, receiving the drug composition when the pH value of the mixture solution is between pH 6 to 7. The hydrophilic drug(s) and the hydrophobic drug(s) are encapsulated simultaneously by one-pot synthesis, and the protein could be modified by one-pot synthesis to provide a drug composition with multiple functions. 1. A preparation method of a drug composition , comprising:dispersing an amphiphilic chitosan derivative, at least a hydrophobic drug, and at least a hydrophilic drug in an solvent to form a mixture solution, wherein the amphiphilic chitosan derivative is modified with a plurality of hydrophilic groups and a plurality of hydrophobic groups, and the pH of the mixture solution is adjusted to a range without precipitating the hydrophilic drug and the hydrophobic drug; andafter stirring the mixture solution for at least 12 hours, receiving the drug composition when the pH of the mixture solution is between 6 to 7.2. The preparation method of claim 1 , wherein claim 1 , by adding an aqueous solution with pH of 8.5 to 12.5 claim 1 , the pH of the mixture solution is adjusted to a range without precipitating the hydrophilic drug and the hydrophobic drug.3. The preparation method of claim 2 , wherein claim 2 , by adding an aqueous solution with pH of 9.0 to 10.5 claim 2 , the pH of the mixture solution is adjusted to a range without precipitating the hydrophilic drug and the hydrophobic drug.4 ...

Подробнее
Номер записи: 94
02-02-2017 дата публикации

NUTRACEUTICAL SUPPLEMENT WITH LACTOBACILLUS RHAMNOSUS

Номер: US20170027999A1
Автор: Heck Bruce E., Kim Dong Hyun
Принадлежит:

Compositions and uses thereof include an admixture of a probiotic and natural phytochemicals that can affect an individual's stem cells and the inflammatory process to reduce underlying symptoms of various health issues, including arthritis, aging, and physical or athletic injuries, thereby facilitating healing and repair of tissues. 1. A dietary supplement , comprising a composition including a synergistic combination of:{'i': 'Lactobacillus rhamnosus;'}ginger; andvitamin D.2Lactobacillus rhamnosusLactobacillus rhamnosus.. The dietary supplement of claim 1 , wherein the comprises about 10 billion CFU of3. The dietary supplement of claim 1 , wherein the ginger comprises about 500 mg ginger.4. The dietary supplement of claim 1 , wherein the vitamin D comprises about 1 claim 1 ,000 IU of vitamin D.5. The dietary supplement of claim 1 , further comprising curcumin.6. The dietary supplement of claim 6 , wherein the curcumin comprises about 350 mg tumeric root extract.7Boswellia. The dietary supplement of claim 1 , further comprising extract.8BoswelliaBoswellia serrata. The dietary supplement of claim 7 , wherein the extract comprises about 500 mg extract.9Boswellia. The dietary supplement of claim 1 , further comprising curcumin and extract.10. The dietary supplement of claim 1 , further comprising green tea extract.11Camellia sinensis. The dietary supplement of claim 10 , wherein the green tea extract comprises about 500 mg of green tea leaf extract of standardized to about 98% polyphenols claim 10 , 80% catechins claim 10 , and 50% epigallocatechin gallate.12Boswellia. The dietary supplement of claim 1 , further comprising extract and green tea extract.13Epidmedium. The dietary supplement of claim 1 , further comprising extract.14EpidmediumEpimedium sagittatum. The dietary supplement of claim 13 , wherein the extract comprises about 500 mg of extract standardized to about 10% icariin.15Epimedium. The dietary supplement of claim 1 , further comprising curcumin and ...

Подробнее
Номер записи: 95
24-04-2014 дата публикации

Edible Product

Номер: US20140112971A1
Автор: Shukla Amita, Shukla Mukta
Принадлежит:

The present invention describes an orally administered edible product designed to provide a health benefit in a delivery formulation that will increase ease of use and thus lead to increased compliance and consumption to promote human health and wellness. 1. An edible product comprised of a mixture containing: (1) at least one plant-based product and (2) at least one lipid-based edible substance wherein said mixture is fully or partially enclosed in an edible coating.2. The edible product of claim 1 , wherein said edible product is intended to have a therapeutic claim 1 , curative or preventative health benefit.3. The health benefit of claim 2 , wherein said health benefit includes prevention or treatment of at least one disease or physical disorder selected from the group comprised of claim 2 , but not limited to: inflammatory diseases claim 2 , cardiovascular diseases claim 2 , metabolic diseases claim 2 , autoimmune diseases claim 2 , bone and joint diseases claim 2 , central nervous system diseases and endocrine disorders.4. The plant-based product of claim 1 , wherein said plant based product can be a crude preparation claim 1 , paste claim 1 , powder or extract selected from the group comprised of claim 1 , but not limited to: the leaves claim 1 , roots claim 1 , stem claim 1 , seeds claim 1 , fruits claim 1 , flowers claim 1 , bark claim 1 , nuts claim 1 , tubers claim 1 , tumors claim 1 , other potentially edible components of a plant or tree claim 1 , and mixtures thereof.5. The extract of wherein said extract is comprised of selected active ingredients of said plant-based product.6. The plant-based product of claim 1 , wherein said plant-based product is selected from the group comprised of claim 1 , but not limited to claim 1 , plant-derived products described in: Western herbal preparations claim 1 , naturopathic medicine claim 1 , Ayurveda claim 1 , Unani medicine claim 1 , Siddhi medicine claim 1 , other systems of alternative plant based medicine ...

Подробнее
Номер записи: 96
24-04-2014 дата публикации

NITRITE COMPOSITIONS AND USES THEREOF

Номер: US20140112983A1
Автор: BOUDREAUX James Douglas, GIORDANO Anthony, KEVIL Christopher, Sonz Paul
Принадлежит: TheraVasc Inc.

The present invention relates to compositions of nitrite and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition of inorganic nitrite, or a pharmaceutically acceptable salt thereof, for supplementation in subjects with diabetes, peripheral artery diseases or in patients with risk factors associated with cardiovascular diseases. 1. A dietary supplement comprising one or more fruit or herbal extracts and at least 5% by weight of a nitrite salt.2. The dietary supplement of claim 1 , wherein the extract is an herbal extract selected form the group consisting of gingko biloba claim 1 , garlic claim 1 , ginger claim 1 , pepper claim 1 , parsley claim 1 , orange claim 1 , yohimbine claim 1 , astragalus claim 1 , catuaba claim 1 , schisandra claim 1 , and sulforaphane.3. The dietary supplement of claim 2 , wherein the herbal extract is a mixture of gingko biloba and garlic or wherein the herbal extract is gingko biloba.4. (canceled)5. The dietary supplement of formulated for steady-state release over a period of about 2 hours to about 24 hours; formulated for daily administration; or formulated for oral administration.67-. (canceled)8. The dietary supplement of claim 1 , wherein the nitrite salt is sodium nitrite claim 1 , potassium nitrite claim 1 , or calcium nitrite.9. The dietary supplement of in the form of a tablet or capsule.10. A method for increasing nitrite levels in a person having a nitrite nutritional deficiency claim 1 , the method comprising administering to the person a supplement of in a dosing regimen sufficient to alleviate the nutritional deficit.11. The method of claim 10 , wherein the dosing regimen administered to a subject results in a plasma level of nitrite of about 0.05 to 0.6 μM; wherein a unit dose of about 0.5 μg/kg to about 1000 μg/kg is administered; or wherein said nitrite nutritional deficiency is a result of dietary ...

Подробнее
Номер записи: 97
29-01-2015 дата публикации

ANALGESICS BASED ON SNAKE VENOMS

Номер: US20150030691A1
Автор: CARLSON Bill, Carpenter Desai Holly E., Rourk Michael J.
Принадлежит:

A homeopathic pain topical analgesic composition based on snake venom is disclosed. The study product also contained of a homeopathic remedy most frequently used for fractures, bruises, and muscle strains due to its analgesic and anti-inflammatory effects. The composition also contained a penetrant component to enhance penetration of the ingredients as well as an analgesic/anti-inflammatory component. The snake venoms used may include those of and A clinical study of a product formulated in this way was effective in promoting relief from muscle pain and discomfort. 1. A topical analgesic composition comprising: water;', 'methocel;', 'glucono-delta-lactone; and', 'benzalkonium chloride;, 'an aqueous preservation vehicle comprising [{'i': 'Naja naja', 'venom; and'}, {'i': 'Crotalus horridus', 'venom;'}], 'a venom component comprisingan analgesic/anti-inflammatory component; anda penetrant component comprising propylene glycol.2. The topical analgesic composition of claim 1 , wherein the analgesic/anti-inflammatory component comprises:{'i': 'Capsicum;'}{'i': 'Boswellia', 'extract;'}{'i': 'Arnica Montana;', 'and'}{'i': 'Curcuma longata.'}3. The topical analgesic composition of claim 1 , wherein the analgesic/anti-inflammatory component comprises:{'i': 'Populus tremula;'}{'i': 'Fraxinus excelsior;', 'and'}{'i': 'Solidago virgaurea.'}4. The topical analgesic composition of claim 1 , wherein the penetrant component further comprises oleic acid and isopropyl alcohol.5. The topical analgesic composition of claim 1 , wherein the penetrant component further comprises menthyl lactate.6. The topical analgesic composition of claim 1 , wherein the penetrant component further comprises linalool.7. The topical analgesic composition of claim 1 , wherein the penetrant component further comprises MSM.8Lachesis muta. The topical analgesic composition of claim 1 , wherein the venom component further comprises venom.9. A topical analgesic composition comprising: water;', 'methocel;', ' ...

Подробнее
Номер записи: 98
01-02-2018 дата публикации

Development of curcumin and piperine loaded double-layered biopolymer based nano delivery systems by using electrospray / coating method

Номер: US20180028447A1
Автор: Oguz BAYRAKTAR, Veliddin Canfeza SEZGIN
Принадлежит: Individual

A double-layered particle having a core layer formed of zein protein, in which the active agent curcumin and/or its derivatives are encapsulated, and an outer shell layer formed of chitosan and/or its derivatives, in which the active agent piperine is encapsulated, and which is coated over the core layer.

Подробнее
Номер записи: 99
01-02-2018 дата публикации

MALE AND FEMALE INFERTILITY HERBAL COMPOSITION

Номер: US20180028591A1
Автор: Ke Shaobin
Принадлежит:

An herbal composition that enhances and promotes fertility in both males and females by nourishing the kidney, regulating the liver and spleen, improving circulation of Qi and blood, and balancing the Yin and Yang through a unique composition consisting of natural herbs known in traditional Chinese medicine. The herbs create a synergy between each other that works to enhance fertility for both males and females. The composition consists of the following herbal ingredients mixed in varying weight percentages. goji berry, dodder seed, red sage root, green orange peel, processed fleece flower root, horny goat weed, codonopsis, raspberry, astragalus root, Chinese yam, white peony root, false daisy, mulberry, curcuma tuber, and cynomorium. The herbal ingredients are cleaned, purified and/or processed prior to formulation. The formulation process is at least partially dependent on the desired means of preparation and administering the composition. 1. An herbal composition for enhancing fertility in males and females , the composition comprising:about 3 to 15 weight percent Fructus Lycii, about 3 to 15 weight percent Semen Cuscutae, about 3 to 10 weight percent Radix Salviae Miltiorrhizae, about 1 to 5 weight percent Pericarpium Citri Reticulatae Viride preparata, about 3 to 15 weight percent Radix Polygoni Multiflori preparata, about 3 to 10 weight percent Herba Epimedii, about 3 to 15 weight percent Radix Codonopsis, about 3 to 15 weight percent Fructus Rubi, about 3 to 10 weight percent Radix Astragali, about 3 to 10 weight percent Rhizoma Dioscoreae, about 3 to 10 weight percent Radix Paeoniae Alba, about 3 to 10 weight percent Herba Ecliptae, about 5 to 10 weight percent Fructus Mori, about 3 to 10 weight percent Radix Curcumae, and about 3 to 10 weight percent Herba Cynomorii.2. The composition of claim 1 , wherein the composition is administered in at least one of the following ways: oral claim 1 , topical claim 1 , suppository claim 1 , intravenous claim 1 , ...

Подробнее
Номер записи: 100